Hubbry Logo
logo
Apoptosis
Community hub

Apoptosis

logo
0 subscribers

Wikipedia

from Wikipedia
Apoptosis
An etoposide-treated DU145 prostate cancer cell exploding into a cascade of apoptotic bodies. The sub images were extracted from a 61-hour time-lapse microscopy video, created using quantitative phase-contrast microscopy. The optical thickness is color-coded. With increasing thickness, color changes from gray to yellow, red, purple and finally black.
See the video at The Cell: An Image Library
Identifiers
MeSHD017209
Anatomical terminology

Apoptosis (from Ancient Greek: ἀπόπτωσις, romanizedapóptōsis, lit. 'falling off') is a form of programmed cell death that occurs in multicellular organisms and in some eukaryotic, single-celled microorganisms such as yeast.[1] Biochemical events lead to characteristic cell changes (morphology) and death.[2] These changes include blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation, DNA fragmentation, and mRNA decay. The average adult human loses 50 to 70 billion cells each day due to apoptosis.[a] For the average human child between 8 and 14 years old, each day the approximate loss is 20 to 30 billion cells.[4]

In contrast to necrosis, which is a form of traumatic cell death that results from acute cellular injury, apoptosis is a highly regulated and controlled process that confers advantages during an organism's life cycle. For example, the separation of fingers and toes in a developing human embryo occurs because cells between the digits undergo a form of apoptosis that is genetically determined.[5] Unlike necrosis, apoptosis produces cell fragments called apoptotic bodies that phagocytes are able to engulf and remove before the contents of the cell can spill out onto surrounding cells and cause damage to them.[6]

Because apoptosis cannot stop once it has begun, it is a highly regulated process. Apoptosis can be initiated through one of two pathways. In the intrinsic pathway the cell kills itself because it senses cell stress, while in the extrinsic pathway the cell kills itself because of signals from other cells. Weak external signals may also activate the intrinsic pathway of apoptosis.[7] Both pathways induce cell death by activating caspases, which are proteases, or enzymes that degrade proteins. The two pathways both activate initiator caspases, which then activate executioner caspases, which then kill the cell by degrading proteins indiscriminately.

In addition to its importance as a biological phenomenon, defective apoptotic processes have been implicated in a wide variety of diseases. Excessive apoptosis causes atrophy, whereas an insufficient amount results in uncontrolled cell proliferation, such as cancer. Some factors like Fas receptors and caspases promote apoptosis, while some members of the Bcl-2 family of proteins inhibit apoptosis.[8]

Discovery and etymology

[edit]

German scientist Carl Vogt was first to describe the principle of apoptosis in 1842. In 1885, anatomist Walther Flemming delivered a more precise description of the process of programmed cell death. However, it was not until 1965 that the topic was resurrected. While studying tissues using electron microscopy, John Kerr at the University of Queensland was able to distinguish apoptosis from traumatic cell death.[9] Following the publication of a paper describing the phenomenon, Kerr was invited to join Alastair Currie, as well as Andrew Wyllie, who was Currie's graduate student,[10] at the University of Aberdeen. In 1972, the trio published a seminal article in the British Journal of Cancer.[11] Kerr had initially used the term programmed cell necrosis, but in the article, the process of natural cell death was called apoptosis. Kerr, Wyllie and Currie credited James Cormack, a professor of Greek language at University of Aberdeen, with suggesting the term apoptosis. Kerr received the Paul Ehrlich and Ludwig Darmstaedter Prize on March 14, 2000, for his description of apoptosis. He shared the prize with Boston biologist H. Robert Horvitz.[12]

For many years, neither "apoptosis" nor "programmed cell death" was a highly cited term. Two discoveries brought cell death from obscurity to a major field of research: identification of the first component of the cell death control and effector mechanisms, and linkage of abnormalities in cell death to human disease, in particular cancer. This occurred in 1988 when it was shown that BCL2, the gene responsible for follicular lymphoma, encoded a protein that inhibited cell death.[13]

The 2002 Nobel Prize in Medicine was awarded to Sydney Brenner, H. Robert Horvitz and John Sulston for their work identifying genes that control apoptosis. The genes were identified by studies in the nematode C. elegans and homologues of these genes function in humans to regulate apoptosis.[14]

John Sulston won the Nobel Prize in Medicine in 2002, for his pioneering research on apoptosis.

In Greek, apoptosis translates to the "falling off" of leaves from a tree.[15] Cormack, professor of Greek language, reintroduced the term for medical use as it had a medical meaning for the Greeks over two thousand years before. Hippocrates used the term to mean "the falling off of the bones". Galen extended its meaning to "the dropping of the scabs". Cormack was no doubt aware of this usage when he suggested the name. Debate continues over the correct pronunciation, with opinion divided between a pronunciation with the second p silent (/æpəˈtoʊsɪs/ ap-ə-TOH-sis[16][17]) and the second p pronounced (/eɪpəpˈtoʊsɪs/ ⓘ).[16][18] In English, the p of the Greek -pt- consonant cluster is typically silent at the beginning of a word (e.g. pterodactyl, Ptolemy), but articulated when used in combining forms preceded by a vowel, as in helicopter or the orders of insects: diptera, lepidoptera, etc.

In the original Kerr, Wyllie & Currie paper,[11] there is a footnote regarding the pronunciation:

We are most grateful to Professor James Cormack of the Department of Greek, University of Aberdeen, for suggesting this term. The word "apoptosis" (ἀπόπτωσις) is used in Greek to describe the "dropping off" or "falling off" of petals from flowers, or leaves from trees. To show the derivation clearly, we propose that the stress should be on the penultimate syllable, the second half of the word being pronounced like "ptosis" (with the "p" silent), which comes from the same root "to fall", and is already used to describe the drooping of the upper eyelid.

Activation mechanisms

[edit]
Control Of The Apoptotic Mechanisms
Control of the apoptotic mechanisms

The initiation of apoptosis is tightly regulated by activation mechanisms, because once apoptosis has begun, it inevitably leads to the death of the cell.[19][2] The two best-understood activation mechanisms are the intrinsic pathway (also called the mitochondrial pathway) and the extrinsic pathway.[20] The intrinsic pathway is activated by intracellular signals generated when cells are stressed and depends on the release of proteins from the intermembrane space of mitochondria.[21] The extrinsic pathway is activated by extracellular ligands binding to cell-surface death receptors, which leads to the formation of the death-inducing signaling complex (DISC).[22]

A cell initiates intracellular apoptotic signaling in response to a stress,[23] which may bring about cell death. The binding of nuclear receptors by glucocorticoids,[24] heat,[24] radiation,[24] nutrient deprivation,[24] viral infection,[24] hypoxia,[24] increased intracellular concentration of free fatty acids[25] and increased intracellular calcium concentration,[26][27] for example, by damage to the membrane, can all trigger the release of intracellular apoptotic signals by a damaged cell. A number of cellular components, such as poly ADP ribose polymerase, may also help regulate apoptosis.[28] Single cell fluctuations have been observed in experimental studies of stress induced apoptosis.[29][30]

Before the actual process of cell death is precipitated by enzymes, apoptotic signals must cause regulatory proteins to initiate the apoptosis pathway. This step allows those signals to cause cell death, or the process to be stopped, should the cell no longer need to die. Several proteins are involved, but two main methods of regulation have been identified: the targeting of mitochondria functionality,[31] or directly transducing the signal via adaptor proteins to the apoptotic mechanisms. An extrinsic pathway for initiation identified in several toxin studies is an increase in calcium concentration within a cell caused by drug activity, which also can cause apoptosis via a calcium binding protease calpain.[32]

Intrinsic pathway

[edit]

The intrinsic pathway is also known as the mitochondrial pathway. Mitochondria are essential to multicellular life. Without them, a cell ceases to respire aerobically and quickly dies. This fact forms the basis for some apoptotic pathways. Apoptotic proteins that target mitochondria affect them in different ways. They may cause mitochondrial swelling through the formation of membrane pores, or they may increase the permeability of the mitochondrial membrane and cause apoptotic effectors to leak out.[24][33] There is also a growing body of evidence indicating that nitric oxide is able to induce apoptosis by helping to dissipate the membrane potential of mitochondria and therefore make it more permeable.[34] Nitric oxide has been implicated in initiating and inhibiting apoptosis through its possible action as a signal molecule of subsequent pathways that activate apoptosis.[35]

During apoptosis, cytochrome c is released from mitochondria through the actions of the proteins Bax and Bak. The mechanism of this release is enigmatic, but appears to stem from a multitude of Bax/Bak homo- and hetero-dimers of Bax/Bak inserted into the outer membrane.[36] Once cytochrome c is released it binds with Apoptotic protease activating factor – 1 (Apaf-1) and ATP, which then bind to pro-caspase-9 to create a protein complex known as an apoptosome. The apoptosome cleaves the pro-caspase to its active form of caspase-9, which in turn cleaves and activates pro-caspase into the effector caspase-3.[37]

Mitochondria also release proteins known as SMACs (second mitochondria-derived activator of caspases) into the cell's cytosol following the increase in permeability of the mitochondria membranes. SMAC binds to proteins that inhibit apoptosis (IAPs) thereby deactivating them, and preventing the IAPs from arresting the process and therefore allowing apoptosis to proceed. IAP also normally suppresses the activity of a group of cysteine proteases called caspases,[38] which carry out the degradation of the cell. Therefore, the actual degradation enzymes can be seen to be indirectly regulated by mitochondrial permeability.[39]

Extrinsic pathway

[edit]
Overview of signal transduction pathways
Overview of TNF (left) and Fas (right) signalling in apoptosis, an example of direct signal transduction

Two theories of the direct initiation of apoptotic mechanisms in mammals have been suggested: the TNF-induced (tumor necrosis factor) model and the Fas-Fas ligand-mediated model, both involving receptors of the TNF receptor (TNFR) family[40] coupled to extrinsic signals.

TNF pathway

[edit]

TNF-alpha is a cytokine produced mainly by activated macrophages, and is the major extrinsic mediator of apoptosis. Most cells in the human body have two receptors for TNF-alpha: TNFR1 and TNFR2. The binding of TNF-alpha to TNFR1 has been shown to initiate the pathway that leads to caspase activation via the intermediate membrane proteins TNF receptor-associated death domain (TRADD) and Fas-associated death domain protein (FADD). cIAP1/2 can inhibit TNF-Îą signaling by binding to TRAF2. FLIP inhibits the activation of caspase-8.[41] Binding of this receptor can also indirectly lead to the activation of transcription factors involved in cell survival and inflammatory responses.[42] However, signalling through TNFR1 might also induce apoptosis in a caspase-independent manner.[43][better source needed] The link between TNF-alpha and apoptosis shows why an abnormal production of TNF-alpha plays a fundamental role in several human diseases, especially in autoimmune diseases. The TNF-alpha receptor superfamily also includes death receptors (DRs), such as DR4 and DR5. These receptors bind to the protein TRAIL and mediate apoptosis. Apoptosis is known to be one of the primary mechanisms of targeted cancer therapy.[44] Luminescent iridium complex-peptide hybrids (IPHs) have recently been designed, which mimic TRAIL and bind to death receptors on cancer cells, thereby inducing their apoptosis.[45]

Fas pathway

[edit]

The fas receptor (First apoptosis signal) – (also known as Apo-1 or CD95) is a transmembrane protein of the TNF family which binds the Fas ligand (FasL).[40] The interaction between Fas and FasL results in the formation of the death-inducing signaling complex (DISC), which contains the FADD, caspase-8 and caspase-10. In some types of cells (type I), processed caspase-8 directly activates other members of the caspase family, and triggers the execution of apoptosis of the cell. In other types of cells (type II), the Fas-DISC starts a feedback loop that spirals into increasing release of proapoptotic factors from mitochondria and the amplified activation of caspase-8.[46]

Common components

[edit]

Following TNF-R1 and Fas activation in mammalian cells[47] a balance between proapoptotic (BAX,[48] BID, BAK, or BAD) and anti-apoptotic (Bcl-Xl and Bcl-2) members of the Bcl-2 family are established. This balance is the proportion of proapoptotic homodimers that form in the outer-membrane of the mitochondrion. The proapoptotic homodimers are required to make the mitochondrial membrane permeable for the release of caspase activators such as cytochrome c and SMAC. Control of proapoptotic proteins under normal cell conditions of nonapoptotic cells is incompletely understood, but in general, Bax or Bak are activated by the activation of BH3-only proteins, part of the Bcl-2 family.[49]

Caspases

[edit]

Caspases play the central role in the transduction of ER apoptotic signals. Caspases are proteins that are highly conserved, cysteine-dependent aspartate-specific proteases. There are two types of caspases: initiator caspases (caspases 2, 8, 9, 10, 11, and 12) and effector caspases (caspases 3, 6, and 7). The activation of initiator caspases requires binding to specific oligomeric activator protein. These active initiator caspases activate the effector caspases through proteolytic cleavage. The active effector caspases then proteolytically degrade a host of intracellular proteins to carry out the cell death program.[50]

Caspase-independent apoptotic pathway

[edit]

There also exists a caspase-independent apoptotic pathway that is mediated by AIF (apoptosis-inducing factor).[51]

Apoptosis model in amphibians

[edit]

The frog Xenopus laevis serves as an ideal model system for the study of the mechanisms of apoptosis. In fact, iodine and thyroxine also stimulate the spectacular apoptosis of the cells of the larval gills, tail and fins in amphibian's metamorphosis, and stimulate the evolution of their nervous system transforming the aquatic, vegetarian tadpole into the terrestrial, carnivorous frog.[52][53][54][55]

Negative regulators of apoptosis

[edit]

Negative regulation of apoptosis inhibits cell death signaling pathways, helping tumors to evade cell death and developing drug resistance. The ratio between anti-apoptotic (Bcl-2) and pro-apoptotic (Bax) proteins determines whether a cell lives or dies.[56][57] Many families of proteins act as negative regulators categorized into either antiapoptotic factors, such as IAPs and Bcl-2 proteins or prosurvival factors like cFLIP, BNIP3, FADD, Akt, and NF-ÎşB.[58]

Proteolytic caspase cascade: Killing the cell

[edit]

Many pathways and signals lead to apoptosis, but these converge on a single mechanism that actually causes the death of the cell. After a cell receives stimulus, it undergoes organized degradation of cellular organelles by activated proteolytic caspases. In addition to the destruction of cellular organelles, mRNA is rapidly and globally degraded by a mechanism that is not yet fully characterized.[59] mRNA decay is triggered very early in apoptosis.

A cell undergoing apoptosis shows a series of characteristic morphological changes. Early alterations include:

  1. Cell shrinkage and rounding occur because of the retraction of lamellipodia and the breakdown of the proteinaceous cytoskeleton by caspases.[60]
  2. The cytoplasm appears dense, and the organelles appear tightly packed.[61]
  1. Chromatin undergoes condensation into compact patches against the nuclear envelope (also known as the perinuclear envelope) in a process known as pyknosis, a hallmark of apoptosis.[62][63]
  2. The nuclear envelope becomes discontinuous and the DNA inside it is fragmented in a process referred to as karyorrhexis. The nucleus breaks into several discrete chromatin bodies or nucleosomal units due to the degradation of DNA.[64]

Apoptosis progresses quickly and its products are quickly removed, making it difficult to detect or visualize on classical histology sections. During karyorrhexis, endonuclease activation leaves short DNA fragments, regularly spaced in size. These give a characteristic "laddered" appearance on agar gel after electrophoresis.[65] Tests for DNA laddering differentiate apoptosis from ischemic or toxic cell death.[66]

Apoptotic cell disassembly

[edit]
Different steps in apoptotic cell disassembly[67]

Before the apoptotic cell is disposed of, there is a process of disassembly. There are three recognized steps in apoptotic cell disassembly:[68]

  1. Membrane blebbing: The cell membrane shows irregular buds known as blebs. Initially these are smaller surface blebs. Later these can grow into larger so-called dynamic membrane blebs.[68] An important regulator of apoptotic cell membrane blebbing is ROCK1 (rho associated coiled-coil-containing protein kinase 1).[69][70]
  2. Formation of membrane protrusions: Some cell types, under specific conditions, may develop different types of long, thin extensions of the cell membrane called membrane protrusions. Three types have been described: microtubule spikes, apoptopodia (feet of death), and beaded apoptopodia (the latter having a beads-on-a-string appearance).[71][72][73] Pannexin 1 is an important component of membrane channels involved in the formation of apoptopodia and beaded apoptopodia.[72]
  3. Fragmentation: The cell breaks apart into multiple vesicles called apoptotic bodies, which undergo phagocytosis. The plasma membrane protrusions may help bring apoptotic bodies closer to phagocytes.[citation needed]

Removal of dead cells

[edit]

The removal of dead cells by neighboring phagocytic cells has been termed efferocytosis.[74] Dying cells that undergo the final stages of apoptosis display phagocytotic molecules, such as phosphatidylserine, on their cell surface.[75] Phosphatidylserine is normally found on the inner leaflet surface of the plasma membrane, but is redistributed during apoptosis to the extracellular surface by a protein known as scramblase.[76] These molecules mark the cell for phagocytosis by cells possessing the appropriate receptors, such as macrophages.[77] The removal of dying cells by phagocytes occurs in an orderly manner without eliciting an inflammatory response.[78] During apoptosis cellular RNA and DNA are separated from each other and sorted to different apoptotic bodies; separation of RNA is initiated as nucleolar segregation.[79]

Pathway knock-outs

[edit]

Many knock-outs have been made in the apoptosis pathways to test the function of each of the proteins. Several caspases, in addition to APAF1 and FADD, have been mutated to determine the new phenotype. In order to create a tumor necrosis factor (TNF) knockout, an exon containing the nucleotides 3704–5364 was removed from the gene.[80] This exon encodes a portion of the mature TNF domain, as well as the leader sequence, which is a highly conserved region necessary for proper intracellular processing. TNF-/- mice develop normally and have no gross structural or morphological abnormalities. However, upon immunization with SRBC (sheep red blood cells), these mice demonstrated a deficiency in the maturation of an antibody response; they were able to generate normal levels of IgM, but could not develop specific IgG levels.[81] Apaf-1 is the protein that turns on caspase 9 by cleavage to begin the caspase cascade that leads to apoptosis.[82] Since a -/- mutation in the APAF-1 gene is embryonic lethal, a gene trap strategy was used in order to generate an APAF-1 -/- mouse. This assay is used to disrupt gene function by creating an intragenic gene fusion. When an APAF-1 gene trap is introduced into cells, many morphological changes occur, such as spina bifida, the persistence of interdigital webs, and open brain.[83] In addition, after embryonic day 12.5, the brain of the embryos showed several structural changes. APAF-1 cells are protected from apoptosis stimuli such as irradiation. A BAX-1 knock-out mouse exhibits normal forebrain formation and a decreased programmed cell death in some neuronal populations and in the spinal cord, leading to an increase in motor neurons.[83]

The caspase proteins are integral parts of the apoptosis pathway, so it follows that knock-outs made have varying damaging results. A caspase 9 knock-out leads to a severe brain malformation [citation needed]. A caspase 8 knock-out leads to cardiac failure and thus embryonic lethality [citation needed]. However, with the use of cre-lox technology, a caspase 8 knock-out has been created that exhibits an increase in peripheral T cells, an impaired T cell response, and a defect in neural tube closure [citation needed]. These mice were found to be resistant to apoptosis mediated by CD95, TNFR, etc. but not resistant to apoptosis caused by UV irradiation, chemotherapeutic drugs, and other stimuli. Finally, a caspase 3 knock-out was characterized by ectopic cell masses in the brain and abnormal apoptotic features such as membrane blebbing or nuclear fragmentation [citation needed]. A remarkable feature of these KO mice is that they have a very restricted phenotype: Casp3, 9, APAF-1 KO mice have deformations of neural tissue and FADD and Casp 8 KO showed defective heart development, however, in both types of KO other organs developed normally and some cell types were still sensitive to apoptotic stimuli suggesting that unknown proapoptotic pathways exist.[citation needed]

Methods for distinguishing apoptotic from necrotic cells

[edit]
Long-term live cell imaging (12h) of multinucleated mouse pre-Adipocyte trying to undergo mitosis. Due to the excess of genetic material the cell fails to replicate and dies by apoptosis.

Label-free live cell imaging, time-lapse microscopy, flow fluorocytometry, and transmission electron microscopy can be used to compare apoptotic and necrotic cells. There are also various biochemical techniques for analysis of cell surface markers (phosphatidylserine exposure versus cell permeability by flow cytometry), cellular markers such as DNA fragmentation[84] (flow cytometry),[85] caspase activation, Bid cleavage, and cytochrome c release (Western blotting). Supernatant screening for caspases, HMGB1, and cytokeratin 18 release can identify primary from secondary necrotic cells. However, no distinct surface or biochemical markers of necrotic cell death have been identified yet, and only negative markers are available. These include absence of apoptotic markers (caspase activation, cytochrome c release, and oligonucleosomal DNA fragmentation) and differential kinetics of cell death markers (phosphatidylserine exposure and cell membrane permeabilization). A selection of techniques that can be used to distinguish apoptosis from necroptotic cells could be found in these references.[86][87][88][89]

Implication in disease

[edit]
A section of mouse liver showing several apoptotic cells, indicated by arrows
A section of mouse liver stained to show cells undergoing apoptosis (orange)
Neonatal cardiomyocytes ultrastructure after anoxia-reoxygenation

Defective pathways

[edit]

The various types of apoptotic pathways contain a multitude of different biochemical components, many of them not yet understood.[90] As a pathway is more or less sequential in nature, removing or modifying one component leads to an effect in another. In a living organism, this can have disastrous effects, often in the form of disease or disorder. A discussion of every disease caused by modification of the various apoptotic pathways would be impractical, but the underlying concept is the same: The normal functioning of the pathway has been disrupted in such a way as to impair the ability of the cell to undergo normal apoptosis. This results in a cell that lives past its "use-by date" and can replicate and pass on any faulty machinery to its progeny, increasing the likelihood of the cell's becoming cancerous or diseased.[91]


A recently described example of this concept in action can be seen in the development of a lung cancer called NCI-H460.[92] The X-linked inhibitor of apoptosis protein (XIAP) is overexpressed in cells of the H460 cell line. XIAPs bind to the processed form of caspase-9 and suppress the activity of apoptotic activator cytochrome c; therefore, overexpression leads to a decrease in the number of proapoptotic agonists. As a consequence, the balance of anti-apoptotic and proapoptotic effectors is upset in favour of the former, and the damaged cells continue to replicate despite being directed to die. Defects in regulation of apoptosis in cancer cells occur often at the level of control of transcription factors. As a particular example, defects in molecules that control transcription factor NF-ÎşB in cancer change the mode of transcriptional regulation and the response to apoptotic signals, to curtail dependence on the tissue that the cell belongs. This degree of independence from external survival signals, can enable cancer metastasis.[93]

Dysregulation of p53

[edit]

The tumor-suppressor protein p53 accumulates when DNA is damaged due to a chain of biochemical factors. Part of this pathway includes alpha-interferon and beta-interferon, which induce transcription of the p53 gene, resulting in the increase of p53 protein level and enhancement of cancer cell-apoptosis.[94] p53 prevents the cell from replicating by stopping the cell cycle at G1, or interphase, to give the cell time to repair; however, it will induce apoptosis if damage is extensive and repair efforts fail.[95] Any disruption to the regulation of the p53 or interferon genes will result in impaired apoptosis and the possible formation of tumors.[96]

Inhibition

[edit]

Inhibition of apoptosis can result in a number of cancers, inflammatory diseases, and viral infections. It was originally believed that the associated accumulation of cells was due to an increase in cellular proliferation, but it is now known that it is also due to a decrease in cell death. The most common of these diseases is cancer, the disease of excessive cellular proliferation, which is often characterized by an overexpression of IAP family members. As a result, the malignant cells experience an abnormal response to apoptosis induction: Cycle-regulating genes (such as p53, ras or c-myc) are mutated or inactivated in diseased cells, and further genes (such as bcl-2) also modify their expression in tumors. Some apoptotic factors are vital during mitochondrial respiration e.g. cytochrome C.[97] Pathological inactivation of apoptosis in cancer cells is correlated with frequent respiratory metabolic shifts toward glycolysis (an observation known as the "Warburg hypothesis".[98]

HeLa cell

[edit]

Apoptosis in HeLa[b] cells is inhibited by proteins produced by the cell; these inhibitory proteins target retinoblastoma tumor-suppressing proteins.[99] These tumor-suppressing proteins regulate the cell cycle, but are rendered inactive when bound to an inhibitory protein.[99] HPV E6 and E7 are inhibitory proteins expressed by the human papillomavirus, HPV being responsible for the formation of the cervical tumor from which HeLa cells are derived.[100] HPV E6 causes p53, which regulates the cell cycle, to become inactive.[101] HPV E7 binds to retinoblastoma tumor suppressing proteins and limits its ability to control cell division.[101] These two inhibitory proteins are partially responsible for HeLa cells' immortality by inhibiting apoptosis to occur.[102]

Treatments

[edit]

The main method of treatment for potential death from signaling-related diseases involves either increasing or decreasing the susceptibility of apoptosis in diseased cells, depending on whether the disease is caused by either the inhibition of or excess apoptosis. For instance, treatments aim to restore apoptosis to treat diseases with deficient cell death and to increase the apoptotic threshold to treat diseases involved with excessive cell death. To stimulate apoptosis, one can increase the number of death receptor ligands (such as TNF or TRAIL), antagonize the anti-apoptotic Bcl-2 pathway, or introduce Smac mimetics to inhibit the inhibitor (IAPs).[56] The addition of agents such as Herceptin, Iressa, or Gleevec works to stop cells from cycling and causes apoptosis activation by blocking growth and survival signaling further upstream. Finally, adding p53-MDM2 complexes displaces p53 and activates the p53 pathway, leading to cell cycle arrest and apoptosis. Many different methods can be used either to stimulate or to inhibit apoptosis in various places along the death signaling pathway.[103]

Apoptosis is a multi-step, multi-pathway cell-death programme that is inherent in every cell of the body. In cancer, the apoptosis cell-division ratio is altered. Cancer treatment by chemotherapy and irradiation kills target cells primarily by inducing apoptosis.[104]

Hyperactive apoptosis

[edit]

On the other hand, loss of control of cell death (resulting in excess apoptosis) can lead to neurodegenerative diseases, hematologic diseases, and tissue damage. Neurons that rely on mitochondrial respiration undergo apoptosis in neurodegenerative diseases such as Alzheimer's[105] and Parkinson's.[106] (an observation known as the "Inverse Warburg hypothesis"[97][107]). Moreover, there is an inverse epidemiological comorbidity between neurodegenerative diseases and cancer.[108] The progression of HIV is directly linked to excess, unregulated apoptosis. In a healthy individual, the number of CD4+ lymphocytes is in balance with the cells generated by the bone marrow; however, in HIV-positive patients, this balance is lost due to an inability of the bone marrow to regenerate CD4+ cells. In the case of HIV, CD4+ lymphocytes die at an accelerated rate through uncontrolled apoptosis, when stimulated.

At the molecular level, hyperactive apoptosis can be caused by defects in signaling pathways that regulate the Bcl-2 family proteins. Increased expression of apoptotic proteins such as BIM, or their decreased proteolysis, leads to cell death and can cause a number of pathologies, depending on the cells where excessive activity of BIM occurs. Cancer cells can escape apoptosis through mechanisms that suppress BIM expression or by increased proteolysis of BIM.[citation needed]

Treatments

[edit]

Treatments aiming to inhibit works to block specific caspases. Finally, the Akt protein kinase promotes cell survival through two pathways. Akt phosphorylates and inhibits Bad (a Bcl-2 family member), causing Bad to interact with the 14-3-3 scaffold, resulting in Bcl dissociation and thus cell survival. Akt also activates IKKÎą, which leads to NF-ÎşB activation and cell survival. Active NF-ÎşB induces the expression of anti-apoptotic genes such as Bcl-2, resulting in inhibition of apoptosis. NF-ÎşB has been found to play both an antiapoptotic role and a proapoptotic role depending on the stimuli utilized and the cell type.[109]

HIV progression

[edit]

The progression of the human immunodeficiency virus infection into AIDS is due primarily to the depletion of CD4+ T-helper lymphocytes in a manner that is too rapid for the body's bone marrow to replenish the cells, leading to a compromised immune system. One of the mechanisms by which T-helper cells are depleted is apoptosis, which results from a series of biochemical pathways:[110]

  1. HIV enzymes deactivate anti-apoptotic Bcl-2. This does not directly cause cell death but primes the cell for apoptosis should the appropriate signal be received. In parallel, these enzymes activate proapoptotic procaspase-8, which does directly activate the mitochondrial events of apoptosis.
  2. HIV may increase the level of cellular proteins that prompt Fas-mediated apoptosis.
  3. HIV proteins decrease the amount of CD4 glycoprotein marker present on the cell membrane.
  4. Released viral particles and proteins present in extracellular fluid are able to induce apoptosis in nearby "bystander" T helper cells.
  5. HIV decreases the production of molecules involved in marking the cell for apoptosis, giving the virus time to replicate and continue releasing apoptotic agents and virions into the surrounding tissue.
  6. The infected CD4+ cell may also receive the death signal from a cytotoxic T cell.

Cells may also die as direct consequences of viral infections. HIV-1 expression induces tubular cell G2/M arrest and apoptosis.[111] The progression from HIV to AIDS is not immediate or even necessarily rapid; HIV's cytotoxic activity toward CD4+ lymphocytes is classified as AIDS once a given patient's CD4+ cell count falls below 200.[112]

Researchers from Kumamoto University in Japan have developed a new method to eradicate HIV in viral reservoir cells, named "Lock-in and apoptosis." Using the synthesized compound Heptanoylphosphatidyl L-Inositol Pentakisphophate (or L-Hippo) to bind strongly to the HIV protein PR55Gag, they were able to suppress viral budding. By suppressing viral budding, the researchers were able to trap the HIV virus in the cell and allow for the cell to undergo apoptosis (natural cell death). Associate Professor Mikako Fujita has stated that the approach is not yet available to HIV patients because the research team has to conduct further research on combining the drug therapy that currently exists with this "Lock-in and apoptosis" approach to lead to complete recovery from HIV.[113]

Viral infection

[edit]

Viral induction of apoptosis occurs when one or several cells of a living organism are infected with a virus, leading to cell death. Cell death in organisms is necessary for the normal development of cells and the cell cycle maturation.[114] It is also important in maintaining the regular functions and activities of cells.

Viruses can trigger apoptosis of infected cells via a range of mechanisms including:

  • Receptor binding
  • Activation of protein kinase R (PKR)
  • Interaction with p53
  • Expression of viral proteins coupled to MHC proteins on the surface of the infected cell, allowing recognition by cells of the immune system (such as natural killer and cytotoxic T cells) that then induce the infected cell to undergo apoptosis.[115]

Canine distemper virus (CDV) is known to cause apoptosis in central nervous system and lymphoid tissue of infected dogs in vivo and in vitro.[116] Apoptosis caused by CDV is typically induced via the extrinsic pathway, which activates caspases that disrupt cellular function and eventually leads to the cells death.[99] In normal cells, CDV activates caspase-8 first, which works as the initiator protein followed by the executioner protein caspase-3.[99] However, apoptosis induced by CDV in HeLa cells does not involve the initiator protein caspase-8. HeLa cell apoptosis caused by CDV follows a different mechanism than that in vero cell lines.[99] This change in the caspase cascade suggests CDV induces apoptosis via the intrinsic pathway, excluding the need for the initiator caspase-8. The executioner protein is instead activated by the internal stimuli caused by viral infection not a caspase cascade.[99]

The Oropouche virus (OROV) is found in the family Bunyaviridae. The study of apoptosis brought on by Bunyaviridae was initiated in 1996, when it was observed that apoptosis was induced by the La Crosse virus into the kidney cells of baby hamsters and into the brains of baby mice.[117]

OROV is a disease that is transmitted between humans by the biting midge (Culicoides paraensis).[118] It is referred to as a zoonotic arbovirus and causes febrile illness, characterized by the onset of a sudden fever known as Oropouche fever.[119]

The Oropouche virus also causes disruption in cultured cells – cells that are cultivated in distinct and specific conditions. An example of this can be seen in HeLa cells, whereby the cells begin to degenerate shortly after they are infected.[117]

With the use of gel electrophoresis, it can be observed that OROV causes DNA fragmentation in HeLa cells. It can be interpreted by counting, measuring, and analyzing the cells of the Sub/G1 cell population.[117] When HeLA cells are infected with OROV, the cytochrome C is released from the membrane of the mitochondria, into the cytosol of the cells. This type of interaction shows that apoptosis is activated via an intrinsic pathway.[114]

In order for apoptosis to occur within OROV, viral uncoating, viral internalization, along with the replication of cells is necessary. Apoptosis in some viruses is activated by extracellular stimuli. However, studies have demonstrated that the OROV infection causes apoptosis to be activated through intracellular stimuli and involves the mitochondria.[117]

Many viruses encode proteins that can inhibit apoptosis.[120] Several viruses encode viral homologs of Bcl-2. These homologs can inhibit proapoptotic proteins such as BAX and BAK, which are essential for the activation of apoptosis. Examples of viral Bcl-2 proteins include the Epstein-Barr virus BHRF1 protein and the adenovirus E1B 19K protein.[121] Some viruses express caspase inhibitors that inhibit caspase activity and an example is the CrmA protein of cowpox viruses. Whilst a number of viruses can block the effects of TNF and Fas. For example, the M-T2 protein of myxoma viruses can bind TNF preventing it from binding the TNF receptor and inducing a response.[122] Furthermore, many viruses express p53 inhibitors that can bind p53 and inhibit its transcriptional transactivation activity. As a consequence, p53 cannot induce apoptosis, since it cannot induce the expression of proapoptotic proteins. The adenovirus E1B-55K protein and the hepatitis B virus HBx protein are examples of viral proteins that can perform such a function.[123]

Viruses can remain intact from apoptosis in particular in the latter stages of infection. They can be exported in the apoptotic bodies that pinch off from the surface of the dying cell, and the fact that they are engulfed by phagocytes prevents the initiation of a host response. This favours the spread of the virus.[122] Prions can cause apoptosis in neurons.

Plants

[edit]

Programmed cell death in plants has a number of molecular similarities to that of animal apoptosis, but it also has differences, notable ones being the presence of a cell wall and the lack of an immune system that removes the pieces of the dead cell. Instead of an immune response, the dying cell synthesizes substances to break itself down and places them in a vacuole that ruptures as the cell dies. Additionally, plants do not contain phagocytic cells, which are essential in the process of breaking down and removing apoptotic bodies.[124] Whether this whole process resembles animal apoptosis closely enough to warrant using the name apoptosis (as opposed to the more general programmed cell death) is unclear.[125][126]

Caspase-independent apoptosis

[edit]

The characterization of the caspases allowed the development of caspase inhibitors, which can be used to determine whether a cellular process involves active caspases. Using these inhibitors, it was discovered that cells can die while displaying a morphology similar to apoptosis without caspase activation.[127] Later studies linked this phenomenon to the release of AIF (apoptosis-inducing factor) from the mitochondria and its translocation into the nucleus mediated by its NLS (nuclear localization signal). Inside the mitochondria, AIF is anchored to the inner membrane. In order to be released, the protein is cleaved by a calcium-dependent calpain protease.[128]

See also

[edit]

Explanatory footnotes

[edit]

Citations

[edit]
  1. ^ Green D (2011). Means to an End: Apoptosis and other Cell Death Mechanisms. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-888-1. Archived from the original on 2020-07-26. Retrieved 2020-05-25.
  2. ^ a b BĂśhm I, Schild H (2003). "Apoptosis: the complex scenario for a silent cell death". Mol Imaging Biol. 5 (1): 2–14. doi:10.1016/S1536-1632(03)00024-6. PMID 14499155.
  3. ^ Alberts, p. 2.
  4. ^ Karam JA (2009). Apoptosis in Carcinogenesis and Chemotherapy. Netherlands: Springer. ISBN 978-1-4020-9597-9.
  5. ^ Elmore S (June 2007). "Apoptosis: a review of programmed cell death". Toxicol Pathol. 35 (4): 495–516. doi:10.1080/01926230701320337. PMC 2117903. PMID 17562483.
  6. ^ Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2008). "Chapter 18 Apoptosis: Programmed Cell Death Eliminates Unwanted Cells". Molecular Biology of the Cell (textbook) (5th ed.). Garland Science. p. 1115. ISBN 978-0-8153-4105-5.
  7. ^ Raychaudhuri S (August 2010). "A minimal model of signaling network elucidates cell-to-cell stochastic variability in apoptosis". PLOS ONE. 5 (8) e11930. arXiv:1009.2294. Bibcode:2010PLoSO...511930R. doi:10.1371/journal.pone.0011930. PMC 2920308. PMID 20711445.
  8. ^ Elmore S (June 2007). "Apoptosis: A Review of Programmed Cell Death". Toxicologic Pathology. 35 (4): 495–516. doi:10.1080/01926230701320337. PMC 2117903. PMID 17562483.
  9. ^ Kerr JF (October 1965). "A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes". The Journal of Pathology and Bacteriology. 90 (2): 419–435. doi:10.1002/path.1700900210. PMID 5849603.
  10. ^ Agency for Science, Technology and Research. "Prof Andrew H. Wyllie – Lecture Abstract". Archived from the original on 2007-11-13. Retrieved 2007-03-30.
  11. ^ a b Kerr JF, Wyllie AH, Currie AR (August 1972). "Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics". British Journal of Cancer. 26 (4): 239–257. doi:10.1038/bjc.1972.33. PMC 2008650. PMID 4561027.
  12. ^ O'Rourke MG, Ellem KA (2000). "John Kerr and apoptosis". The Medical Journal of Australia. 173 (11–12): 616–617. doi:10.5694/j.1326-5377.2000.tb139362.x. PMID 11379508. S2CID 38265127.
  13. ^ Vaux DL, Cory S, Adams JM (September 1988). "Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells". Nature. 335 (6189): 440–2. Bibcode:1988Natur.335..440V. doi:10.1038/335440a0. PMID 3262202. S2CID 23593952.
  14. ^ "The Nobel Prize in Physiology or Medicine 2002". NobelPrize.org. Retrieved 2025-01-13.
  15. ^ Alberts, p. 1021.
  16. ^ a b "The American Heritage Dictionary entry: apoptosis". ahdictionary.com. Houghton Mifflin Harcourt Publishing Company. 2020. Archived from the original on 26 July 2021. Retrieved 26 July 2021.
  17. ^ Apoptosis Interest Group (1999). "About apoptosis". Archived from the original on 28 December 2006. Retrieved 2006-12-15.
  18. ^ "Definition of apoptosis". www.webster.com. Archived from the original on 2007-07-03. Retrieved 2007-08-11.
  19. ^ Alberts, p. 1029.
  20. ^ Alberts, p. 1023.
  21. ^ Alberts, p. 1032.
  22. ^ Alberts, p. 1024.
  23. ^ Nirmala, J. Grace; Lopus, Manu (2020). "Cell death mechanisms in eukaryotes". Cell Biology and Toxicology. 36 (2): 145–164. doi:10.1007/s10565-019-09496-2. ISSN 1573-6822. PMID 31820165. S2CID 208869679.
  24. ^ a b c d e f g Cotran RS, Kumar C (1998). Robbins Pathologic Basis of Disease. Philadelphia: W.B Saunders Company. ISBN 978-0-7216-7335-6.
  25. ^ Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M, Langelier Y (August 2003). "Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin". The Journal of Biological Chemistry. 278 (34): 31861–31870. doi:10.1074/jbc.m300190200. PMID 12805375.
  26. ^ Mattson MP, Chan SL (December 2003). "Calcium orchestrates apoptosis". Nature Cell Biology. 5 (12): 1041–1043. doi:10.1038/ncb1203-1041. PMID 14647298. S2CID 38427579. Archived from the original on 2019-11-21. Retrieved 2018-05-18.
  27. ^ Uğuz AC, Naziroğlu M, Espino J, Bejarano I, GonzĂĄlez D, RodrĂ­guez AB, Pariente JA (December 2009). "Selenium modulates oxidative stress-induced cell apoptosis in human myeloid HL-60 cells through regulation of calcium release and caspase-3 and -9 activities". The Journal of Membrane Biology. 232 (1–3): 15–23. doi:10.1007/s00232-009-9212-2. PMID 19898892. S2CID 22215706.
  28. ^ Chiarugi A, Moskowitz MA (July 2002). "Cell biology. PARP-1--a perpetrator of apoptotic cell death?". Science. 297 (5579): 200–201. doi:10.1126/science.1074592. PMID 12114611. S2CID 82828773.
  29. ^ Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR (March 2000). "The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant". Nature Cell Biology. 2 (3): 156–162. doi:10.1038/35004029. PMID 10707086. S2CID 2283955.
  30. ^ Lee JK, Lu S, Madhukar A (October 2010). "Real-Time dynamics of Ca2+, caspase-3/7, and morphological changes in retinal ganglion cell apoptosis under elevated pressure". PLOS ONE. 5 (10) e13437. Bibcode:2010PLoSO...513437L. doi:10.1371/journal.pone.0013437. PMC 2956638. PMID 20976135.
  31. ^ Bejarano I, Espino J, GonzĂĄlez-Flores D, Casado JG, Redondo PC, Rosado JA, et al. (September 2009). "Role of Calcium Signals on Hydrogen Peroxide-Induced Apoptosis in Human Myeloid HL-60 Cells". International Journal of Biomedical Science. 5 (3): 246–256. doi:10.59566/IJBS.2009.5246. PMC 3614781. PMID 23675144.
  32. ^ Moon, Dong-Oh (19 May 2023). "Calcium's Role in Orchestrating Cancer Apoptosis: Mitochondrial-Centric Perspective". International Journal of Molecular Sciences. 24 (10): 8982. doi:10.3390/ijms24108982. PMC 10218825. PMID 37240331.
  33. ^ Gonzalez D, Bejarano I, Barriga C, Rodriguez AB, Pariente JA (2010). "Oxidative Stress-Induced Caspases are Regulated in Human Myeloid HL-60 Cells by Calcium Signal". Current Signal Transduction Therapy. 5 (2): 181–186. doi:10.2174/157436210791112172.
  34. ^ BrĂźne B (August 2003). "Nitric oxide: NO apoptosis or turning it ON?". Cell Death and Differentiation. 10 (8): 864–869. doi:10.1038/sj.cdd.4401261. PMID 12867993.
  35. ^ BrĂźne B, von Knethen A, Sandau KB (October 1999). "Nitric oxide (NO): an effector of apoptosis". Cell Death and Differentiation. 6 (10): 969–975. doi:10.1038/sj.cdd.4400582. PMID 10556974.
  36. ^ Uren RT, Iyer S, Kluck RM (August 2017). "Pore formation by dimeric Bak and Bax: an unusual pore?". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 372 (1726) 20160218. doi:10.1098/rstb.2016.0218. PMC 5483520. PMID 28630157.
  37. ^ Li, Peng; Nijhawan, Deepak; Budihardjo, Imawati; Srinivasula, Srinivasa M; Ahmad, Manzoor; Alnemri, Emad S; Wang, Xiaodong (November 1997). "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade". Cell. 91 (4): 479–489. doi:10.1016/S0092-8674(00)80434-1. ISSN 0092-8674. PMID 9390557.
  38. ^ Fesik SW, Shi Y (November 2001). "Structural biology. Controlling the caspases". Science. 294 (5546): 1477–1478. doi:10.1126/science.1062236. PMID 11711663. S2CID 11392850.
  39. ^ McCarthy, Nancy (2008). "Smac it to them!". Nature Reviews Cancer. 8 (5): 345. Retrieved 11 October 2025.
  40. ^ a b Wajant H (May 2002). "The Fas signaling pathway: more than a paradigm". Science. 296 (5573): 1635–1636. Bibcode:2002Sci...296.1635W. doi:10.1126/science.1071553. PMID 12040174. S2CID 29449108.
  41. ^ Chen G, Goeddel DV (May 2002). "TNF-R1 signaling: a beautiful pathway". Science. 296 (5573): 1634–1635. Bibcode:2002Sci...296.1634C. doi:10.1126/science.1071924. PMID 12040173. S2CID 25321662.
  42. ^ Goeddel, DV (2007). "Connection Map for Tumor Necrosis Factor Pathway". Science's STKE. 2007 (382) tw132. doi:10.1126/stke.3822007tw132. S2CID 85404086. Archived from the original on 2009-07-10. Retrieved 2004-01-01.
  43. ^ Chen W, Li N, Chen T, Han Y, Li C, Wang Y, et al. (December 2005). "The lysosome-associated apoptosis-inducing protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway". The Journal of Biological Chemistry. 280 (49): 40985–40995. doi:10.1074/jbc.M502190200. PMC 8144674. PMID 16188880. (Retracted, see doi:10.1016/j.jbc.2021.100764)
  44. ^ Gerl R, Vaux DL (February 2005). "Apoptosis in the development and treatment of cancer". Carcinogenesis. 26 (2): 263–270. doi:10.1093/carcin/bgh283. PMID 15375012.
  45. ^ Masum AA, Yokoi K, Hisamatsu Y, Naito K, Shashni B, Aoki S (September 2018). "Design and synthesis of a luminescent iridium complex-peptide hybrid (IPH) that detects cancer cells and induces their apoptosis". Bioorganic & Medicinal Chemistry. 26 (17): 4804–4816. doi:10.1016/j.bmc.2018.08.016. PMID 30177492. S2CID 52149418.
  46. ^ Wajant H (2007). "Connection Map for Fas Signaling Pathway". Science's STKE. 2007 (380): tr1. doi:10.1126/stke.3802007tr1. S2CID 84909531. Archived from the original on 2009-05-03. Retrieved 2004-01-01.
  47. ^ Qian, Shuting; Zhang, Changzheng; Zhang, Shiyu; Liu, Xiaojun; Chen, Shuang (2022). "The role of BCL-2 family proteins in regulating apoptosis". Cell & Bioscience. 12 (1): 92. doi:10.1186/s13578-022-00868-0 (inactive 12 October 2025). PMC 9597512. PMID 36259069. The BID activation pathway is generally activated by caspase 8 in response to FAS/TNF-R1 death receptor signaling … Following activation, the balance between pro-apoptotic and anti-apoptotic Bcl-2 family members regulates mitochondrial outer membrane permeabilization.{{cite journal}}: CS1 maint: DOI inactive as of October 2025 (link)
  48. ^ Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB (January 2000). "Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells". Cell Death and Differentiation. 7 (1): 102–111. doi:10.1038/sj.cdd.4400597. PMID 10713725.
  49. ^ Westphal D, Kluck RM, Dewson G (February 2014). "Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis". Cell Death and Differentiation. 21 (2): 196–205. doi:10.1038/cdd.2013.139. PMC 3890949. PMID 24162660.
  50. ^ Shalini, S.; Dorstyn, L.; Dawar, S.; Kumar, S. (2015). "Caspases in cell death, inflammation and disease". Nature Reviews Molecular Cell Biology. 16 (11): 726–738. PMC 6611727. PMID 26462713. The apoptotic caspases can be further sub-categorized in initiator- and executioner caspases. The caspases-8, -9 and -10 initiate apoptosis through the activation of the executioner caspases-3, -6 and -7.
  51. ^ Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. (February 1999). "Molecular characterization of mitochondrial apoptosis-inducing factor". Nature. 397 (6718): 441–446. Bibcode:1999Natur.397..441S. doi:10.1038/17135. PMID 9989411. S2CID 204991081.
  52. ^ Jewhurst K, Levin M, McLaughlin KA (2014). "Optogenetic Control of Apoptosis in Targeted Tissues of Xenopus laevis Embryos". Journal of Cell Death. 7: 25–31. doi:10.4137/JCD.S18368. PMC 4213186. PMID 25374461.
  53. ^ Venturi S (2011). "Evolutionary Significance of Iodine". Current Chemical Biology. 5 (3): 155–62. doi:10.2174/187231311796765012 (inactive 1 July 2025).{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
  54. ^ Venturi, Sebastiano (2014). "Iodine, PUFAs and Iodolipids in Health and Disease: An Evolutionary Perspective". Human Evolution. 29 (1–3): 185–205. ISSN 0393-9375.
  55. ^ Tamura K, Takayama S, Ishii T, Mawaribuchi S, Takamatsu N, Ito M (June 2015). "Apoptosis and differentiation of Xenopus tail-derived myoblasts by thyroid hormone". Journal of Molecular Endocrinology. 54 (3): 185–192. doi:10.1530/JME-14-0327. PMID 25791374.
  56. ^ a b Jan R, Chaudhry GE (June 2019). "Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics". Advanced Pharmaceutical Bulletin. 9 (2): 205–218. doi:10.15171/apb.2019.024. PMC 6664112. PMID 31380246.
  57. ^ Kale J, Osterlund EJ, Andrews DW (January 2018). "BCL-2 family proteins: changing partners in the dance towards death". Cell Death and Differentiation. 25 (1): 65–80. doi:10.1038/cdd.2017.186. PMC 5729540. PMID 29149100.
  58. ^ Razaghi A, Heimann K, Schaeffer PM, Gibson SB (February 2018). "Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies". Apoptosis. 23 (2): 93–112. doi:10.1007/s10495-018-1440-4. PMID 29322476. S2CID 3424489.
  59. ^ Thomas MP, Liu X, Whangbo J, McCrossan G, Sanborn KB, Basar E, et al. (May 2015). "Apoptosis Triggers Specific, Rapid, and Global mRNA Decay with 3' Uridylated Intermediates Degraded by DIS3L2". Cell Reports. 11 (7): 1079–1089. doi:10.1016/j.celrep.2015.04.026. PMC 4862650. PMID 25959823.
  60. ^ BĂśhm I (May 2003). "Disruption of the cytoskeleton after apoptosis induction with autoantibodies". Autoimmunity. 36 (3): 183–189. doi:10.1080/0891693031000105617. PMID 12911286. S2CID 37887253.
  61. ^ Elmore, Susan (2007). "Apoptosis: A Review of Programmed Cell Death". Toxicologic Pathology. 35 (4): 495–516. doi:10.1080/01926230701320337. PMC 2117903. PMID 17562483. With cell shrinkage, the cells are smaller in size, the cytoplasm is dense and the organelles are more tightly packed.
  62. ^ Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, et al. (August 2000). "Two distinct pathways leading to nuclear apoptosis". The Journal of Experimental Medicine. 192 (4): 571–580. doi:10.1084/jem.192.4.571. PMC 2193229. PMID 10952727.
  63. ^ Kihlmark M, Imreh G, Hallberg E (October 2001). "Sequential degradation of proteins from the nuclear envelope during apoptosis". Journal of Cell Science. 114 (Pt 20): 3643–3653. doi:10.1242/jcs.114.20.3643. PMID 11707516.
  64. ^ Nagata S (April 2000). "Apoptotic DNA fragmentation". Experimental Cell Research. 256 (1): 12–18. doi:10.1006/excr.2000.4834. PMID 10739646.
  65. ^ Gong J, Traganos F, Darzynkiewicz Z (May 1994). "A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry". Analytical Biochemistry. 218 (2): 314–319. doi:10.1006/abio.1994.1184. PMID 8074286.
  66. ^ Iwata M, Myerson D, Torok-Storb B, Zager RA (December 1994). "An evaluation of renal tubular DNA laddering in response to oxygen deprivation and oxidant injury". Journal of the American Society of Nephrology. 5 (6): 1307–1313. doi:10.1681/ASN.V561307. PMID 7893995.
  67. ^ Smith A, Parkes MA, Atkin-Smith GK, Tixeira R, Poon IK (2017). "Cell disassembly during apoptosis". WikiJournal of Medicine. 4 (1). doi:10.15347/wjm/2017.008.
  68. ^ a b Tixeira R, Caruso S, Paone S, Baxter AA, Atkin-Smith GK, Hulett MD, Poon IK (March 2017). "Defining the morphologic features and products of cell disassembly during apoptosis". Apoptosis. 22 (3): 475–477. doi:10.1007/s10495-017-1345-7. PMID 28102458. S2CID 34648758.
  69. ^ Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF (April 2001). "Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I". Nature Cell Biology. 3 (4): 339–345. doi:10.1038/35070009. PMID 11283606. S2CID 2537726.
  70. ^ Sebbagh M, RenvoizĂŠ C, Hamelin J, RichĂŠ N, Bertoglio J, BrĂŠard J (April 2001). "Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing". Nature Cell Biology. 3 (4): 346–352. doi:10.1038/35070019. PMID 11283607. S2CID 36187702.
  71. ^ Moss DK, Betin VM, Malesinski SD, Lane JD (June 2006). "A novel role for microtubules in apoptotic chromatin dynamics and cellular fragmentation". Journal of Cell Science. 119 (Pt 11): 2362–2374. doi:10.1242/jcs.02959. PMC 1592606. PMID 16723742.
  72. ^ a b Poon IK, Chiu YH, Armstrong AJ, Kinchen JM, Juncadella IJ, Bayliss DA, Ravichandran KS (March 2014). "Unexpected link between an antibiotic, pannexin channels and apoptosis". Nature. 507 (7492): 329–334. Bibcode:2014Natur.507..329P. doi:10.1038/nature13147. PMC 4078991. PMID 24646995.
  73. ^ Atkin-Smith GK, Tixeira R, Paone S, Mathivanan S, Collins C, Liem M, et al. (June 2015). "A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure". Nature Communications. 6 7439. Bibcode:2015NatCo...6.7439A. doi:10.1038/ncomms8439. PMC 4490561. PMID 26074490.
  74. ^ Vandivier RW, Henson PM, Douglas IS (June 2006). "Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease". Chest. 129 (6): 1673–1682. doi:10.1378/chest.129.6.1673. PMID 16778289.
  75. ^ Li MO, Sarkisian MR, Mehal WZ, Rakic P, Flavell RA (November 2003). "Phosphatidylserine receptor is required for clearance of apoptotic cells". Science. 302 (5650): 1560–1563. Bibcode:2003Sci...302.1560O. doi:10.1126/science.1087621. PMID 14645847. S2CID 36252352.
  76. ^ Wang X, Wu YC, Fadok VA, Lee MC, Gengyo-Ando K, Cheng LC, et al. (November 2003). "Cell corpse engulfment mediated by C. elegans phosphatidylserine receptor through CED-5 and CED-12". Science. 302 (5650): 1563–1566. Bibcode:2003Sci...302.1563W. doi:10.1126/science.1087641. PMID 14645848. S2CID 25672278. Archived from the original on 2021-04-14. Retrieved 2017-02-26.
  77. ^ Savill J, Gregory C, Haslett C (November 2003). "Cell biology. Eat me or die". Science. 302 (5650): 1516–1517. doi:10.1126/science.1092533. hdl:1842/448. PMID 14645835. S2CID 13402617.
  78. ^ Krysko DV, Vandenabeele P (2009-01-14). Krysko DV, Vandenabeele P (eds.). Phagocytosis of dying cells: from molecular mechanisms to human diseases. Springer. doi:10.1007/978-1-4020-9293-0. ISBN 978-1-4020-9292-3. Archived from the original on 2022-04-30. Retrieved 2017-08-28.
  79. ^ Halicka HD, Bedner E, Darzynkiewicz Z (November 2000). "Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis". Experimental Cell Research. 260 (2): 248–256. doi:10.1006/excr.2000.5027. PMID 11035919.
  80. ^ Wang C, Youle RJ (2009-12-01). "The role of mitochondria in apoptosis". Annual Review of Genetics. 43 (1): 95–118. doi:10.1146/annurev-genet-102108-134850. PMC 4762029. PMID 19659442.
  81. ^ Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. (July 1997). "Characterization of tumor necrosis factor-deficient mice". Proceedings of the National Academy of Sciences of the United States of America. 94 (15): 8093–8098. Bibcode:1997PNAS...94.8093M. doi:10.1073/pnas.94.15.8093. PMC 21562. PMID 9223320.
  82. ^ Bratton SB, Salvesen GS (October 2010). "Regulation of the Apaf-1-caspase-9 apoptosome". Journal of Cell Science. 123 (Pt 19): 3209–3214. doi:10.1242/jcs.073643. PMC 2939798. PMID 20844150.
  83. ^ a b Mailhos C, Howard MK, Latchman DS (April 1994). "A common pathway mediates retinoic acid and PMA-dependent programmed cell death (apoptosis) of neuronal cells". Brain Research. 644 (1): 7–12. doi:10.1016/0006-8993(94)90339-5. PMID 8032951. S2CID 22542598.
  84. ^ Lozano GM, Bejarano I, Espino J, González D, Ortiz A, García JF, Rodríguez AB, Pariente JA (2009). "Density gradient capacitation is the most suitable method to improve fertilization and to reduce DNA fragmentation positive spermatozoa of infertile men". Anatolian Journal of Obstetrics & Gynecology. 3 (1): 1–7. Archived from the original on 2022-04-30. Retrieved 2016-03-08.
  85. ^ Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F (January 1997). "Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis)". Cytometry. 27 (1): 1–20. doi:10.1002/(sici)1097-0320(19970101)27:1<1::aid-cyto2>3.0.co;2-l. PMID 9000580.
  86. ^ Krysko DV, Vanden Berghe T, Parthoens E, D'Herde K, Vandenabeele P (2008). "Chapter 16 Methods for Distinguishing Apoptotic from Necrotic Cells and Measuring Their Clearance". Programmed Cell Death, General Principles for Studying Cell Death, Part A. Methods in Enzymology. Vol. 442. pp. 307–41. doi:10.1016/S0076-6879(08)01416-X. ISBN 978-0-12-374312-1. PMID 18662577.
  87. ^ Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P (March 2008). "Apoptosis and necrosis: detection, discrimination and phagocytosis". Methods. 44 (3): 205–221. doi:10.1016/j.ymeth.2007.12.001. PMID 18314051.
  88. ^ Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N, Vandenabeele P (June 2013). "Determination of apoptotic and necrotic cell death in vitro and in vivo". Methods. 61 (2): 117–129. doi:10.1016/j.ymeth.2013.02.011. PMID 23473780. Archived from the original on 2019-11-05. Retrieved 2019-11-05.
  89. ^ Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z (2011). "Apoptosis and beyond: cytometry in studies of programmed cell death". Recent Advances in Cytometry, Part B – Advances in Applications. Methods in Cell Biology. Vol. 103. pp. 55–98. doi:10.1016/B978-0-12-385493-3.00004-8. ISBN 978-0-12-385493-3. PMC 3263828. PMID 21722800.
  90. ^ Thompson CB (March 1995). "Apoptosis in the pathogenesis and treatment of disease". Science. 267 (5203): 1456–1462. Bibcode:1995Sci...267.1456T. doi:10.1126/science.7878464. PMID 7878464. S2CID 12991980.
  91. ^ Hassan, Mohamed; Watari, Hidemichi; AbuAlmaaty, Amr; Ohba, Shingo; Sakuragi, Noriaki (2014). "Apoptosis and molecular targeting therapy in cancer". BioMed Research International. 2014: 1–23. doi:10.1155/2014/150845. PMC 3384434. PMID 25013758. Alterations of apoptotic signaling pathways lead to human diseases. Both reduced and increased apoptosis can result in pathology. Dysregulation of apoptosis plays a crucial role in the pathogenesis of many cancers, autoimmune diseases, and neurodegenerative disorders.
  92. ^ Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, et al. (February 2003). "Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide". Cancer Research. 63 (4): 831–837. PMID 12591734. Archived from the original on 2012-12-20. Retrieved 2008-09-04.
  93. ^ Vlahopoulos SA (August 2017). "Aberrant control of NF-ÎşB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode". Cancer Biology & Medicine. 14 (3): 254–270. doi:10.20892/j.issn.2095-3941.2017.0029. PMC 5570602. PMID 28884042.
  94. ^ Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. (July 2003). "Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence". Nature. 424 (6948): 516–523. Bibcode:2003Natur.424..516T. doi:10.1038/nature01850. PMID 12872134.
  95. ^ Bernstein C, Bernstein H, Payne CM, Garewal H (June 2002). "DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis". Mutation Research. 511 (2): 145–178. Bibcode:2002MRRMR.511..145B. doi:10.1016/S1383-5742(02)00009-1. PMID 12052432.
  96. ^ Soussi, Thierry (2000). "The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation". Annals of the New York Academy of Sciences. 910 (1): 121–139. Bibcode:2000NYASA.910..121S. doi:10.1111/j.1749-6632.2000.tb06705.x. ISSN 1749-6632. PMID 10911910.
  97. ^ a b Kaczanowski S (May 2016). "Apoptosis: its origin, history, maintenance and the medical implications for cancer and aging" (PDF). Physical Biology. 13 (3) 031001. Bibcode:2016PhBio..13c1001K. doi:10.1088/1478-3975/13/3/031001. PMID 27172135. S2CID 5549982. Archived from the original (PDF) on 2019-04-28. Retrieved 2019-12-26.
  98. ^ Warburg O (February 1956). "On the origin of cancer cells". Science. 123 (3191): 309–314. Bibcode:1956Sci...123..309W. doi:10.1126/science.123.3191.309. PMID 13298683.
  99. ^ a b c d e f Del Puerto HL, Martins AS, Milsted A, Souza-Fagundes EM, Braz GF, Hissa B, et al. (June 2011). "Canine distemper virus induces apoptosis in cervical tumor derived cell lines". Virology Journal. 8 (1) 334. doi:10.1186/1743-422X-8-334. PMC 3141686. PMID 21718481.
  100. ^ Liu HC, Chen GG, Vlantis AC, Tse GM, Chan AT, van Hasselt CA (March 2008). "Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16". Journal of Cellular Biochemistry. 103 (4): 1125–1143. doi:10.1002/jcb.21490. PMID 17668439. S2CID 1651475.
  101. ^ a b Niu XY, Peng ZL, Duan WQ, Wang H, Wang P (2006). "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo". International Journal of Gynecological Cancer. 16 (2): 743–751. doi:10.1111/j.1525-1438.2006.00384.x (inactive 1 July 2025). PMID 16681755.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
  102. ^ Liu Y, McKalip A, Herman B (May 2000). "Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation". Journal of Cellular Biochemistry. 78 (2): 334–349. doi:10.1002/(sici)1097-4644(20000801)78:2<334::aid-jcb15>3.3.co;2-6. PMID 10842327.
  103. ^ Boehm I (June 2006). "Apoptosis in physiological and pathological skin: implications for therapy". Current Molecular Medicine. 6 (4): 375–394. doi:10.2174/156652406777435390. PMID 16900661.
  104. ^ Lowe, Scott W.; Lin, Albert W. (2000-03-01). "Apoptosis in cancer". Carcinogenesis. 21 (3): 485–495. doi:10.1093/carcin/21.3.485. PMID 10688869. Retrieved 2025-01-22.
  105. ^ LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G (January 1995). "The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice". Nature Genetics. 9 (1): 21–30. doi:10.1038/ng0195-21. PMID 7704018. S2CID 20016461.
  106. ^ Mochizuki H, Goto K, Mori H, Mizuno Y (May 1996). "Histochemical detection of apoptosis in Parkinson's disease". Journal of the Neurological Sciences. 137 (2): 120–123. doi:10.1016/0022-510X(95)00336-Z. PMID 8782165. S2CID 44329454.
  107. ^ Demetrius LA, Magistretti PJ, Pellerin L (2014). "Alzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect". Frontiers in Physiology. 5: 522. doi:10.3389/fphys.2014.00522. PMC 4294122. PMID 25642192.
  108. ^ Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C, et al. (July 2013). "Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study". Neurology. 81 (4): 322–328. doi:10.1212/WNL.0b013e31829c5ec1. PMID 23843468. S2CID 22792702.
  109. ^ Farhana L, Dawson MI, Fontana JA (June 2005). "Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation". Cancer Research. 65 (11): 4909–4917. doi:10.1158/0008-5472.CAN-04-4124. PMID 15930313.
  110. ^ Alimonti JB, Ball TB, Fowke KR (July 2003). "Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS". The Journal of General Virology. 84 (Pt 7): 1649–1661. doi:10.1099/vir.0.19110-0. PMID 12810858.
  111. ^ Vashistha H, Husain M, Kumar D, Yadav A, Arora S, Singhal PC (2008). "HIV-1 expression induces tubular cell G2/M arrest and apoptosis". Renal Failure. 30 (6): 655–664. doi:10.1080/08860220802134672. PMID 18661417. S2CID 25787186.
  112. ^ Indiana University Health. "AIDS Defining Criteria | Riley". IU Health. Archived from the original on 2013-05-26. Retrieved 2013-01-20.
  113. ^ Tateishi H, Monde K, Anraku K, Koga R, Hayashi Y, Ciftci HI, et al. (August 2017). "A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis"". Scientific Reports. 7 (1) 8957. Bibcode:2017NatSR...7.8957T. doi:10.1038/s41598-017-09129-w. PMC 5567282. PMID 28827668.
  114. ^ a b Indran IR, Tufo G, Pervaiz S, Brenner C (June 2011). "Recent advances in apoptosis, mitochondria and drug resistance in cancer cells". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1807 (6): 735–745. doi:10.1016/j.bbabio.2011.03.010. PMID 21453675.
  115. ^ Everett H, McFadden G (April 1999). "Apoptosis: an innate immune response to virus infection". Trends in Microbiology. 7 (4): 160–165. doi:10.1016/S0966-842X(99)01487-0. PMID 10217831.
  116. ^ Nishi T, Tsukiyama-Kohara K, Togashi K, Kohriyama N, Kai C (November 2004). "Involvement of apoptosis in syncytial cell death induced by canine distemper virus". Comparative Immunology, Microbiology and Infectious Diseases. 27 (6): 445–455. doi:10.1016/j.cimid.2004.01.007. PMID 15325517.
  117. ^ a b c d Acrani GO, Gomes R, Proença-MĂłdena JL, da Silva AF, Carminati PO, Silva ML, et al. (April 2010). "Apoptosis induced by Oropouche virus infection in HeLa cells is dependent on virus protein expression". Virus Research. 149 (1): 56–63. doi:10.1016/j.virusres.2009.12.013. PMID 20080135.
  118. ^ Azevedo RS, Nunes MR, Chiang JO, Bensabath G, Vasconcelos HB, Pinto AY, et al. (June 2007). "Reemergence of Oropouche fever, northern Brazil". Emerging Infectious Diseases. 13 (6): 912–915. doi:10.3201/eid1306.061114. PMC 2792853. PMID 17553235.
  119. ^ Santos RI, Rodrigues AH, Silva ML, Mortara RA, Rossi MA, Jamur MC, et al. (December 2008). "Oropouche virus entry into HeLa cells involves clathrin and requires endosomal acidification". Virus Research. 138 (1–2): 139–143. doi:10.1016/j.virusres.2008.08.016. PMC 7114418. PMID 18840482.
  120. ^ Teodoro JG, Branton PE (March 1997). "Regulation of apoptosis by viral gene products". Journal of Virology. 71 (3): 1739–1746. doi:10.1128/jvi.71.3.1739-1746.1997. PMC 191242. PMID 9032302.
  121. ^ Polster BM, Pevsner J, Hardwick JM (March 2004). "Viral Bcl-2 homologs and their role in virus replication and associated diseases". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1644 (2–3): 211–227. doi:10.1016/j.bbamcr.2003.11.001. PMID 14996505.
  122. ^ a b Hay S, Kannourakis G (July 2002). "A time to kill: viral manipulation of the cell death program". The Journal of General Virology. 83 (Pt 7): 1547–1564. CiteSeerX 10.1.1.322.6923. doi:10.1099/0022-1317-83-7-1547. PMID 12075073.
  123. ^ Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, StĂźrzbecher HW, et al. (December 1995). "Abrogation of p53-induced apoptosis by the hepatitis B virus X gene". Cancer Research. 55 (24): 6012–6016. PMID 8521383.
  124. ^ van Doorn WG, Beers EP, Dangl JL, Franklin-Tong VE, Gallois P, Hara-Nishimura I, et al. (August 2011). "Morphological classification of plant cell deaths". Cell Death and Differentiation. 18 (8): 1241–1246. doi:10.1038/cdd.2011.36. PMC 3172093. PMID 21494263.
  125. ^ Collazo C, Chacón O, Borrás O (2006). "Programmed cell death in plants resembles apoptosis of animals" (PDF). Biotecnología Aplicada. 23: 1–10. Archived from the original (PDF) on 2009-03-03.
  126. ^ Dickman M, Williams B, Li Y, de Figueiredo P, Wolpert T (October 2017). "Reassessing apoptosis in plants". Nature Plants. 3 (10): 773–779. Bibcode:2017NatPl...3..773D. doi:10.1038/s41477-017-0020-x. PMID 28947814. S2CID 3290201.
  127. ^ Xiang J, Chao DT, Korsmeyer SJ (December 1996). "BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases". Proceedings of the National Academy of Sciences of the United States of America. 93 (25): 14559–14563. Bibcode:1996PNAS...9314559X. doi:10.1073/pnas.93.25.14559. PMC 26172. PMID 8962091.
  128. ^ Polster, Brian M.; Basanez, Gloria; Etxebarria, Amaya; Hardwick, J. Marie; Nicholls, David G. (2005). "Calpain I Induces Cleavage and Release of Apoptosis-Inducing Factor from Isolated Mitochondria". The Journal of Biological Chemistry. 280 (8): 6447–6454. doi:10.1074/jbc.M413269200. PMID 15590628.
  129. ^ Kim JH, Lee CH (September 2009). "Atromentin-induced apoptosis in human leukemia U937 cells". Journal of Microbiology and Biotechnology. 19 (9): 946–950. doi:10.4014/jmb.0811.617. PMID 19809251. S2CID 11552839.

General bibliography

[edit]
[edit]

Grokipedia

from Grokipedia
Apoptosis is a genetically programmed and regulated form of cell death that eliminates unnecessary, damaged, or harmful cells in a controlled manner, characterized by distinct morphological changes such as cell shrinkage, chromatin condensation, DNA fragmentation into nucleosomal units, and plasma membrane blebbing, followed by rapid phagocytosis by neighboring cells without provoking inflammation.[1] This process is ATP-dependent and enzyme-driven, primarily executed through a cascade of cysteine-aspartic proteases known as caspases, which dismantle cellular components in an orderly fashion.[2] The mechanisms of apoptosis are mediated by two primary signaling pathways: the intrinsic pathway, triggered by internal cellular stresses like DNA damage or oxidative stress, which involves mitochondrial outer membrane permeabilization and the release of cytochrome c to activate initiator caspases; and the extrinsic pathway, initiated by external death ligands such as tumor necrosis factor (TNF) or Fas ligand binding to death receptors, leading to caspase-8 activation.[2] These pathways often converge on effector caspases (e.g., caspases-3, -6, and -7) that cleave key substrates, resulting in the systematic breakdown of the cytoskeleton, nuclear envelope, and DNA.[3] Regulatory proteins, including the Bcl-2 family (anti-apoptotic members like Bcl-2 and pro-apoptotic ones like Bax) and inhibitors of apoptosis proteins (IAPs), fine-tune the process to prevent aberrant activation.[3] Apoptosis plays a crucial role in embryonic development, where it sculpts tissues and organs by eliminating excess cells—for instance, separating digits in the developing paw or resorbing the tadpole tail during metamorphosis—and in adult tissues, it maintains homeostasis by balancing cell proliferation, with billions of cells undergoing apoptosis daily in organs like the bone marrow and intestine.[3] Dysregulation of apoptosis contributes to numerous diseases: excessive apoptosis is implicated in neurodegenerative disorders like Alzheimer's, while insufficient apoptosis allows uncontrolled cell survival in cancers and autoimmune conditions.[2] Ongoing research targets apoptotic pathways for therapeutic interventions, such as enhancing apoptosis in tumors via BH3 mimetics or inhibiting it in degenerative diseases.[1]

Definition and Characteristics

Definition

Apoptosis is a genetically regulated form of programmed cell death that orchestrates controlled cellular suicide to preserve organismal homeostasis. This process relies on energy-dependent enzymatic activities, primarily involving ATP, and proceeds without provoking inflammation, distinguishing it from uncontrolled forms of cell death such as necrosis.[4][3][5] The concept of apoptosis was first formally described in 1972 by John F. R. Kerr, Andrew H. Wyllie, and Alastair R. Currie as a fundamental biological mechanism of cell deletion, complementary yet opposite to mitosis in regulating tissue kinetics.[6] Apoptosis serves to eliminate damaged, superfluous, or hazardous cells, thereby maintaining balanced cell populations across physiological contexts including embryonic development, tissue remodeling in adulthood, aging, and responses to environmental or genotoxic stress.[2][4][7] At its core, apoptosis entails a non-random, sequential dismantling of cellular architecture by caspases and other proteases, facilitating efficient clearance by phagocytes and averting the leakage of intracellular material that could incite autoimmunity or collateral tissue injury.[8][9][10]

Morphological and Biochemical Features

Apoptosis is characterized by distinct morphological alterations that distinguish it from other forms of cell death. These include cellular shrinkage, where the cell volume decreases due to cytoskeletal breakdown and water efflux, accompanied by chromatin condensation known as pyknosis, which begins peripherally in the nucleus and progresses to a dense, uniform mass.[6] Subsequent nuclear fragmentation, or karyorrhexis, results in multiple discrete nuclear bodies. These nuclear changes, including pyknosis and karyorrhexis, are particularly evident in apoptotic leukocytes such as neutrophils and monocytes. Light microscopy with Giemsa (or Wright's Giemsa) staining reveals pyknotic nuclei with condensed chromatin and karyorrhexis (nuclear fragmentation), while fluorescence microscopy using Hoechst 33342 staining visualizes condensed and fragmented nuclei as brightly fluorescent structures.[11][12] The cytoplasm exhibits membrane blebbing, forming bubble-like protrusions that detach as intact apoptotic bodies containing nuclear fragments, organelles, and cytosol.[13] These apoptotic bodies are rapidly phagocytosed by neighboring cells or macrophages, preventing inflammatory responses.[14] Biochemically, apoptosis features specific molecular hallmarks that reflect ordered enzymatic processes. A prominent marker is DNA laddering, where genomic DNA is cleaved into internucleosomal fragments of approximately 180-200 base pairs (or multiples thereof) by caspase-activated DNase (CAD), producing a characteristic ladder pattern upon agarose gel electrophoresis. This fragmentation arises from the activation of CAD by effector caspases during the early stages of apoptosis, contrasting with the random DNA degradation seen in necrosis.[15] Another key biochemical event is the externalization of phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane, an early indicator of apoptosis that signals for recognition and clearance by phagocytes. This PS flip is mediated by the inactivation of aminophospholipid translocases and activation of scramblases, exposing PS on the cell surface without compromising membrane integrity. The exposure can be detected through binding of annexin V, a calcium-dependent phospholipid-binding protein, which serves as a sensitive assay for early apoptotic cells in flow cytometry.[3] Throughout most of apoptosis, the plasma membrane remains intact, avoiding the release of intracellular contents and secondary necrosis, which helps maintain tissue homeostasis; this differs from necrosis, where early membrane rupture leads to uncontrolled leakage and inflammation.[14]

History and Etymology

Discovery Timeline

The concept of programmed cell death emerged gradually through observations of physiological processes in developing organisms. In 1842, German anatomist Carl Vogt first described spontaneous cell death as a normal physiological event during the metamorphosis of the midwife toad, noting the elimination of notochord cells to facilitate vertebral formation.[16] This early recognition highlighted cell death as an integral part of development rather than mere pathology, though it remained underexplored for over a century. Subsequent histological studies in the mid-19th century, such as those by Rudolf Virchow, further formalized cell death in the context of cellular pathology, but distinguished pathological necrosis from what would later be termed apoptosis.[17] Significant advances occurred in the mid-20th century with studies on invertebrate models. In 1964, Richard A. Lockshin and Carroll M. Williams detailed programmed cell death in the intersegmental muscles of silkmoth pupae, demonstrating how hormonal signals trigger orderly tissue breakdown during metamorphosis and introducing the idea of "programmed" cell death as a regulated process.[18] This work laid foundational insights into non-pathological cell elimination. Building on such observations, in 1972, John F.R. Kerr, Andrew H. Wyllie, and Alastair R. Currie coined the term "apoptosis" (from Greek, meaning "falling off," like leaves) to characterize a distinct, energy-dependent form of cell death observed in the normal rat liver and ventral prostate gland, explicitly differentiating it from the uncontrolled swelling and rupture of necrosis through morphological features like chromatin condensation and apoptotic bodies.[6] The 1980s marked the molecular era of apoptosis research, revealing key regulators. In 1988, David L. Vaux, Suzanne Cory, and Jerry M. Adams demonstrated that the bcl-2 proto-oncogene, translocated in follicular lymphomas, functions as an apoptosis suppressor by promoting hematopoietic cell survival and cooperating with c-myc to immortalize pre-B cells, shifting the paradigm from proliferation to survival in oncogenesis.[19] The following year, in 1989, Robert A. Black and colleagues identified interleukin-1β converting enzyme (ICE, later known as caspase-1) as a cysteine protease responsible for cleaving the inactive precursor of the proinflammatory cytokine IL-1β, providing the first hint of proteases in cell death signaling. The 1990s brought rapid elucidation of core components and pathways. In 1990, Bernhard C. Trauth and colleagues described the APO-1 antigen (later identified as Fas or CD95), a cell surface receptor whose monoclonal antibody triggering induced apoptosis in lymphoid cells, establishing it as a key mediator of programmed death. By 1993, Scott W. Lowe, Elizabeth M. Schmitt, and Tyler Jacks showed that the tumor suppressor p53 is essential for apoptosis in response to DNA damage, such as ionizing radiation, in mouse thymocytes, linking p53 to cell death as a safeguard against tumorigenesis. The decade culminated in the full characterization of the caspase cascade by 1997, with studies like those by Salvesen and Dixit revealing ICE-like proteases (caspases) as a hierarchical executioner system activated sequentially to dismantle the cell in an orderly manner.[20] These discoveries were recognized in 2002 when the Nobel Prize in Physiology or Medicine was awarded to Sydney Brenner, H. Robert Horvitz, and John E. Sulston for their pioneering genetic studies on organ development and programmed cell death in the nematode Caenorhabditis elegans, which identified key genes like ced-3 and ced-9 homologous to mammalian caspases and bcl-2.

Etymology and Terminology

The term apoptosis derives from the ancient Greek words apo- (ἀπό), meaning "from" or "off," and ptōsis (πτῶσις), meaning "falling," evoking the image of leaves gently detaching and falling from a tree in an orderly, seasonal manner. This etymology was deliberately chosen by pathologists John F. R. Kerr, Andrew H. Wyllie, and Alastair R. Currie in their 1972 paper to characterize a form of non-pathological cell death that involves controlled, active cellular shedding without eliciting an inflammatory response, distinguishing it from the disruptive process of necrosis.[13] Prior to the introduction of apoptosis, Kerr had described the phenomenon in 1971 as "shrinkage necrosis," emphasizing its unique morphological pattern of cell contraction and fragmentation observed in various tissues, separate from the swelling and lysis typical of necrosis. The 1972 publication in the British Journal of Cancer elevated the term apoptosis, replacing earlier vague descriptors such as "physiological cell death" and providing a standardized nomenclature for this regulated process in vertebrate tissues.[21][13] Over time, apoptosis has become the preferred term for this specific type of cell death in animals, particularly vertebrates, where it manifests through distinct biochemical and morphological features. It is often contrasted with the broader concept of "programmed cell death" (PCD), which encompasses genetically orchestrated cell elimination across diverse organisms and includes non-apoptotic mechanisms; the two are not synonymous, as apoptosis specifically denotes the characteristic "shrinking" morphology without implying all forms of PCD.[13][22]

Molecular Pathways

Intrinsic Pathway

The intrinsic pathway of apoptosis, also known as the mitochondrial pathway, represents a primary internal mechanism for programmed cell death, initiated by cellular stresses that signal irreparable damage. This pathway integrates diverse intracellular signals to orchestrate a controlled dismantling of the cell, primarily through mitochondrial dysfunction.[23] Key triggers of the intrinsic pathway include DNA damage, oxidative stress, and growth factor deprivation, which collectively disrupt cellular homeostasis and promote apoptotic signaling. In response to DNA damage, the tumor suppressor protein p53 is activated, leading to transcriptional upregulation of pro-apoptotic genes such as those encoding Bax and Bak, which facilitates their oligomerization on the mitochondrial outer membrane.[23] This p53-mediated activation ensures that severe genotoxic stress tips the balance toward cell elimination to prevent potential oncogenic transformation.[24] A pivotal event in the pathway is mitochondrial outer membrane permeabilization (MOMP), driven by the oligomerization of Bax and Bak proteins, which form pores in the membrane and enable the release of cytochrome c from the mitochondrial intermembrane space into the cytosol.[25] Once released, cytochrome c interacts with Apaf-1 in the presence of dATP, inducing a conformational change that promotes the assembly of the apoptosome—a wheel-like complex comprising multiple Apaf-1 molecules, cytochrome c, and procaspase-9. The apoptosome then recruits and autoactivates procaspase-9 into active caspase-9, which subsequently cleaves and activates executioner caspases to propagate the death signal.[23] Central to the regulation of MOMP and cytochrome c release are the Bcl-2 family proteins, which function as a rheostat for apoptotic commitment. Pro-apoptotic members, including the multi-domain effectors Bax and Bak, as well as the BH3-only activator Bid, drive membrane permeabilization, while anti-apoptotic proteins such as Bcl-2 and Bcl-xL counteract this by binding and sequestering pro-apoptotic counterparts.[26] BH3-only proteins like Bim serve as stress sensors, directly activating Bax/Bak or inhibiting Bcl-2/Bcl-xL upon detecting cellular perturbations such as endoplasmic reticulum stress or developmental cues.[23] Through this dynamic interplay, the intrinsic pathway finely tunes cell fate decisions by weighing survival versus death signals from multiple internal sources.[26]

Extrinsic Pathway

The extrinsic pathway of apoptosis is a receptor-mediated process triggered by extracellular death signals, primarily from immune cells, that enables rapid elimination of unwanted or infected cells. This pathway is initiated when death ligands bind to specific death receptors belonging to the tumor necrosis factor (TNF) receptor superfamily, such as Fas ligand (FasL) binding to Fas (CD95) or TNF-Îą binding to TNFR1. These interactions induce receptor trimerization on the cell surface, facilitating the recruitment of intracellular adaptor proteins and the formation of the death-inducing signaling complex (DISC). Key events in the extrinsic pathway involve the adaptor protein Fas-associated death domain (FADD), which binds to the death domain of the activated receptor via its own death domain, while its death effector domain recruits procaspase-8 to the DISC. Within the DISC, procaspase-8 undergoes proximity-induced dimerization and autocatalytic cleavage, generating active initiator caspase-8. Caspase-8 then propagates the apoptotic signal by cleaving downstream effector caspases, such as caspase-3 and -7, leading to cellular disassembly.[27] Cells respond to extrinsic signals through two distinct subtypes: Type I cells, which exhibit robust DISC formation and direct activation of effector caspases by caspase-8 without mitochondrial involvement, and Type II cells, where caspase-8 cleaves the BH3-only protein Bid to tBid, which translocates to mitochondria to amplify the signal via the intrinsic pathway. This bifurcation allows flexibility in apoptotic commitment based on cellular context. A notable example is the TNF-related apoptosis-inducing ligand (TRAIL), which binds to TRAIL receptors (DR4 and DR5) and selectively induces apoptosis in many cancer cells while sparing most normal cells, due to differential expression and sensitivity of these receptors.[28] Overall, the extrinsic pathway provides a swift mechanism for immune surveillance, such as cytotoxic T lymphocytes or natural killer cells delivering death ligands to target virally infected or autoreactive cells, thereby maintaining tissue homeostasis without eliciting inflammation.[29]

Caspase-Independent Pathways

Caspase-independent pathways of apoptosis provide alternative routes for programmed cell death when caspase activation is inhibited or absent, ensuring the elimination of damaged or unwanted cells through distinct molecular effectors. These pathways often overlap with caspase-dependent mechanisms in their initiation but diverge in execution, relying on proteins released from mitochondria or lysosomes to induce nuclear changes and cell dismantling. Such pathways serve as safeguards in scenarios like caspase knockouts or viral infections where caspase inhibitors are deployed, and they contribute to resistance against caspase-targeted therapies in cancer cells.[30] A primary mechanism involves the release of apoptosis-inducing factor (AIF) from the mitochondrial intermembrane space following mitochondrial outer membrane permeabilization (MOMP), typically triggered by pro-apoptotic Bcl-2 family proteins such as Bax and Bak. Upon release, AIF translocates to the nucleus, where it binds DNA and promotes peripheral chromatin condensation and large-scale (~50 kb) DNA fragmentation without requiring caspase activity; this process is inhibited by anti-apoptotic Bcl-2. AIF was identified in the late 1990s as a flavoprotein with oxidoreductase activity that shifts to an apoptogenic role during stress signals like DNA damage or oxidative stress. In caspase-deficient models, such as Apaf-1 knockout mice, AIF-mediated death becomes prominent, highlighting its role in embryonic development and neuronal injury.[31][30][32] Another mitochondrial effector is endonuclease G (EndoG), a nuclease released alongside AIF during MOMP, which independently translocates to the nucleus to execute oligonucleotide-sized DNA fragmentation, resembling the laddering seen in caspase-dependent apoptosis but without caspase involvement. EndoG's activity is evolutionarily conserved across eukaryotes and is activated by similar intrinsic triggers, including Bax/Bak oligomerization, but it operates as a backup in cells lacking Apaf-1 or caspase-9. Discovered in the early 2000s, EndoG complements AIF by targeting DNA directly and has been implicated in caspase-independent death during viral infections, where it ensures host cell elimination despite viral caspase suppression.[33][34][30] Lysosomal cathepsins, particularly cathepsins B and D, contribute to caspase-independent apoptosis by leaking from destabilized lysosomes into the cytosol, where they act as proteases to cleave Bid and other substrates, amplifying mitochondrial release of AIF and EndoG. This pathway can be initiated by death receptor signaling, such as TNF, independent of the full apoptosome, and cathepsins execute cell death by degrading structural proteins. Studies from the late 1990s onward showed cathepsins dominating in certain tumor cells resistant to caspase inhibitors, underscoring their therapeutic relevance in cancer where lysosomal permeabilization bypasses caspase blockade.[35][30][36] In immune-mediated apoptosis, granzyme B from cytotoxic T cells or natural killer cells induces caspase-independent death by directly cleaving Bid to trigger MOMP and AIF/EndoG release, or by processing downstream substrates like ROCK II for membrane blebbing, even when caspases are inhibited. This mechanism, elucidated in the late 1990s, ensures target cell killing in caspase-deficient contexts, such as during certain viral evasions, and provides a perforin-dependent pathway robust against caspase antagonists.[37][38][30]

Regulation of Apoptosis

Positive Regulators

Positive regulators of apoptosis are molecules and proteins that actively promote the activation of apoptotic pathways, tipping the cellular balance toward programmed cell death in response to signals indicating irreparable damage, such as DNA lesions or developmental cues. These regulators ensure the precise execution of apoptosis to maintain tissue homeostasis and eliminate potentially harmful cells.[39] A central positive regulator is the tumor suppressor protein p53, which acts as a transcriptional activator of pro-apoptotic genes in response to cellular stress. Upon activation, p53 directly upregulates genes encoding BH3-only proteins, including Puma and Noxa, which are essential for initiating mitochondrial outer membrane permeabilization and subsequent caspase activation. For instance, Puma, identified as a p53-upregulated modulator of apoptosis, encodes a BH3 domain-only protein that binds and antagonizes anti-apoptotic Bcl-2 family members, thereby facilitating cytochrome c release from mitochondria. Similarly, Noxa, another p53-inducible BH3-only protein, selectively inhibits Mcl-1 to promote apoptosis in various cell types exposed to genotoxic stress.[40][41] BH3-only members of the Bcl-2 family, such as Bad and Noxa, serve as critical sensors of apoptotic signals and inhibit anti-apoptotic proteins like Bcl-2 and Bcl-xL. Bad, for example, heterodimerizes with Bcl-xL in its dephosphorylated form, displacing pro-apoptotic Bax and Bak to trigger mitochondrial permeabilization. These proteins integrate diverse upstream signals, including growth factor deprivation or DNA damage, to amplify the death signal within the intrinsic pathway. In the extrinsic pathway, death receptors such as Fas (CD95) and tumor necrosis factor receptor 1 (TNFR1) function as positive regulators by recruiting adaptor proteins like FADD upon ligand binding, leading to caspase-8 activation and downstream executioner caspase engagement. Ligand-induced trimerization of Fas initiates a death-inducing signaling complex (DISC) that propagates the apoptotic signal rapidly in immune cells.[42] Mitochondrial intermembrane space proteins like Smac/DIABLO also promote apoptosis by antagonizing inhibitors of apoptosis proteins (IAPs). During the intrinsic pathway, Smac/DIABLO is released alongside cytochrome c, binding to XIAP and cIAP1 to relieve their inhibition of caspases-3, -7, and -9, thereby enhancing caspase cascade amplification.[43] Post-2010 research has further elucidated the role of microRNAs (miRNAs) in positively regulating p53-mediated apoptosis, with miR-34 family members acting in a feedback loop to enhance p53 activity. miR-34a, directly transcribed by p53, represses negative regulators like SIRT1 and HDAC1, thereby amplifying p53-dependent transcription of pro-apoptotic targets and sensitizing cells to death signals in response to DNA damage.[44]

Negative Regulators

Negative regulators of apoptosis encompass a suite of proteins that inhibit cell death pathways, ensuring cellular survival under physiological conditions and preventing unwarranted tissue damage. These inhibitors primarily target key executioners such as caspases and pro-apoptotic effectors, maintaining a delicate balance that supports development, homeostasis, and responses to stress.[45] The Bcl-2 family of anti-apoptotic proteins, including Bcl-2 and Mcl-1, represents a central class of negative regulators acting at the mitochondria in the intrinsic pathway. These multi-domain proteins possess four Bcl-2 homology (BH) domains and inhibit apoptosis by sequestering pro-apoptotic family members like Bax and Bak, thereby preventing mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and subsequent caspase activation. Bcl-2 was first identified in follicular lymphoma due to t(14;18) chromosomal translocation, highlighting its role in promoting cell survival. Mcl-1 similarly binds BH3-only activators such as Bim and Bid, stabilizing mitochondrial integrity and suppressing apoptotic signaling.[26][26][46] Inhibitors of apoptosis proteins (IAPs), such as XIAP and survivin, provide another layer of control by directly antagonizing caspases. XIAP binds and inhibits executioner caspases-3 and -7 via its BIR2 domain and initiator caspase-9 via BIR3, blocking their catalytic activity and often promoting ubiquitination for degradation; this sets a high threshold for caspase-mediated cell death. Survivin, with its single BIR domain, similarly suppresses caspase-9 and interacts with Smac/DIABLO to counteract pro-apoptotic signals, while also exhibiting E3 ubiquitin ligase activity that modulates its own localization and function. These IAPs are overexpressed in various cancers, where they confer resistance to apoptotic stimuli.[47][47][48] In the extrinsic pathway, c-FLIP (cellular FLICE-like inhibitory protein) serves as a key negative regulator by interfering with death receptor signaling. c-FLIP isoforms, particularly c-FLIPL and c-FLIPS, are recruited to the death-inducing signaling complex (DISC) via their death effector domains (DEDs), where they competitively bind FADD and procaspase-8, preventing the autocatalytic activation of caspase-8 and halting downstream apoptotic amplification. At high levels, c-FLIPL forms heterodimers with caspase-8 that lack full proteolytic activity, further dampening the response.[49][49] By inhibiting these core mechanisms, negative regulators avert excessive cell loss that could disrupt tissue homeostasis, as seen in developmental processes where balanced apoptosis sculpts organs without over-depletion. However, their overexpression dysregulates this balance, contributing to pathologies; for instance, elevated Bcl-2 and IAPs in cancers like leukemia and lymphoma enable tumor persistence and therapy resistance, while in autoimmune diseases such as systemic lupus erythematosus, heightened anti-apoptotic activity sustains autoreactive lymphocytes.[45][45][50] Recent insights from the 2020s highlight cross-talk between apoptosis and necroptosis mediated by RIPK1 (receptor-interacting protein kinase 1), where its inhibition modulates pathway outcomes to favor survival. In the PANoptosome complex, RIPK1 acts dually: its kinase activity promotes necroptosis via RIPK3/MLKL, but as a scaffold, it recruits FADD-caspase-8 to drive apoptosis; pharmacological inhibition of RIPK1 (e.g., by Nec-1s) suppresses necroptosis while enhancing regulated apoptosis, thereby preventing inflammatory cell lysis and excessive tissue damage in contexts like neurological disorders. This regulatory node underscores how negative control of RIPK1 integrates apoptotic restraint with alternative death pathways.[51][51]

Execution and Consequences

Caspase Cascade

The caspase cascade represents the proteolytic execution phase of apoptosis, where a series of cysteine-aspartic proteases known as caspases are activated in a hierarchical manner to dismantle the cell.[52] These enzymes are synthesized as inactive zymogen precursors (procaspases) and become activated through specific proteolytic processing, leading to an irreversible commitment to programmed cell death.[53] Caspases are classified into initiator and effector groups based on their structural features and roles in the apoptotic process. Initiator caspases, such as caspase-8, -9, and -10, possess long prodomains that facilitate their recruitment to activation platforms like the death-inducing signaling complex or apoptosome, where they undergo autoactivation.[54] Effector caspases, including caspase-3, -6, and -7, have short prodomains and are activated by cleavage from initiator caspases, subsequently targeting a broad array of cellular substrates.[52] Notably, caspase-1, originally identified in 1989 as the interleukin-1β-converting enzyme (ICE) for its role in processing pro-IL-1β, belongs to the inflammatory caspase subfamily but exhibits cross-talk with apoptotic pathways, particularly in pyroptosis-related contexts.[55][56] Activation of procaspases occurs primarily through induced proximity and dimerization, which promotes intermolecular cleavage at specific aspartic acid (Asp) residues within the zymogen. For initiator caspases, recruitment to oligomeric complexes brings procaspases into close proximity, enabling low-level autocatalytic activity that generates active dimers; this process is enhanced by cleavage at conserved Asp sites, such as Asp315 in caspase-9.[57] Effector procaspases, like procaspase-3, are then transactivated by these initiator enzymes through similar Asp-directed proteolysis, forming the mature heterotetrameric active enzyme.80430-4) This zymogen processing is highly specific, requiring recognition of Asp in the P1 position of the cleavage site (e.g., DEVD for caspase-3 substrates), ensuring precise and ordered activation. The caspase cascade functions as an amplification loop, where initial activation of a few initiator molecules triggers the processing of numerous effector caspases, creating a rapid and irreversible proteolytic chain reaction.[53] For instance, active caspase-9 can cleave procaspase-3, which in turn processes additional caspase-9, establishing positive feedback that overcomes inhibitory mechanisms like IAPs.[57] Effector caspases then cleave hundreds of intracellular substrates, including poly(ADP-ribose) polymerase (PARP) for DNA repair inhibition and nuclear lamins for nuclear envelope breakdown, systematically disassembling cellular architecture.[52] This coordinated proteolysis ensures efficient cell death execution, with the cascade's design preventing premature activation in healthy cells.[54]

Cellular Disassembly and Clearance

During the execution phase of apoptosis, effector caspases systematically dismantle cellular structures by cleaving key substrates. Caspase-3 activates gelsolin, an actin-binding protein, by proteolytic cleavage at the DQTD site, generating a constitutively active fragment that depolymerizes filamentous actin (F-actin) and disrupts cytoskeletal integrity.[58] This cleavage promotes cytoskeletal collapse, membrane blebbing, and cell shrinkage, essential for morphological changes in apoptosis.[59] Similarly, caspases target actin directly, producing fragments such as the 15 kDa C-terminal tActin, which further contributes to structural breakdown.[59] Caspases also cleave poly(ADP-ribose) polymerase-1 (PARP-1) at the DEVD site, inactivating its DNA repair function and preventing ATP depletion that could otherwise lead to necrosis.[58] PARP cleavage conserves cellular energy for the apoptotic program, facilitating DNA fragmentation and chromatin condensation.[4] These proteolytic events, following activation in the caspase cascade, culminate in the fragmentation of the cell into membrane-bound apoptotic bodies containing cytoplasmic organelles and nuclear fragments.[4] Apoptotic bodies maintain plasma membrane integrity, distinguishing this ordered disassembly from uncontrolled necrosis.[4] To ensure non-inflammatory removal, apoptotic cells expose "eat-me" signals on their surface, primarily phosphatidylserine (PS), which translocates from the inner to the outer plasma membrane leaflet via scramblases like Xkr8.[60] Phagocytes recognize PS directly through receptors such as TIM-4, BAI1, and Stabilin-2, or indirectly via bridging molecules like MFG-E8, Gas6, and C1q.[60] Additional signals include calreticulin, which emerges on the cell surface during endoplasmic reticulum stress and binds the low-density lipoprotein receptor-related protein (LRP/CD91) on phagocytes to initiate efferocytosis.[61] Thrombospondin cooperates with PS by binding it and engaging CD36 and vitronectin receptors on macrophages, enhancing recognition of apoptotic cells like neutrophils.[62] Efficient clearance by phagocytes prevents secondary necrosis and inflammation, as apoptotic bodies are engulfed and degraded in lysosomes without releasing danger signals.[62] Defective clearance, as observed in systemic lupus erythematosus (SLE), results in apoptotic debris accumulation, secondary necrosis, and release of proinflammatory signals like HMGB1, promoting autoantibody production and autoimmune responses.[63] Recent studies highlight the role of LC3-associated phagocytosis (LAP), a noncanonical autophagy pathway, in optimizing apoptotic cell clearance; LAP recruits LC3 to phagosomes via receptors like TIM-4 and ROS from NOX2, accelerating lysosomal fusion and degradation while suppressing inflammation.[64] In neutrophils, LAP facilitates efferocytosis during inflammation, reducing NETosis and promoting resolution.[65]

Detection Methods

Distinguishing Apoptosis from Necrosis

Apoptosis and necrosis represent two distinct forms of cell death, differing fundamentally in their mechanisms, morphological features, and physiological consequences. Apoptosis is a programmed, tightly regulated process that maintains tissue homeostasis by eliminating unnecessary or damaged cells in an orderly manner, whereas necrosis is typically an uncontrolled response to severe cellular injury, leading to passive cell demise. These differences were first systematically described in a seminal study that highlighted apoptosis as an active biological phenomenon contrasting with the passive disintegration seen in necrosis. Key distinctions can be observed at morphological, biochemical, and inflammatory levels. Morphologically, apoptotic cells undergo shrinkage, chromatin condensation, and membrane blebbing to form intact apoptotic bodies that are rapidly phagocytosed, preserving plasma membrane integrity throughout. In contrast, necrotic cells exhibit swelling (oncosis), organelle dilation, and eventual rupture of the plasma membrane, resulting in uncontrolled leakage of intracellular contents. Biochemically, apoptosis involves ATP-dependent activation of caspases, leading to specific proteolysis of cellular components and ordered DNA fragmentation into internucleosomal units ("DNA laddering") mediated by caspase-activated DNase. Necrosis, being ATP-independent, features random, non-specific DNA degradation and activation of degradative enzymes like calpains without caspase involvement.[66][67][68] A critical difference lies in their impact on inflammation: apoptosis is non-inflammatory and even immunosuppressive, as it promotes the exposure of "eat-me" signals like phosphatidylserine, facilitating rapid clearance by phagocytes to prevent damage-associated molecular pattern (DAMP) release and inflammation. However, delayed clearance can lead to caspase-3-mediated cleavage of gasdermin E, inducing secondary pyroptosis.[69] Necrosis, however, provokes a robust inflammatory response through the release of DAMPs, cytokines, and other intracellular molecules from ruptured cells, alerting the immune system to tissue damage. This inflammatory potential underscores necrosis as an accidental event, often triggered by ischemia or toxins, while apoptosis serves adaptive roles in development and surveillance.[68][67][66] While these forms are generally distinct, hybrid or regulated variants like necroptosis blur the boundaries; necroptosis is a programmed necrosis dependent on RIPK3 and MLKL, sharing necrotic morphology and inflammatory outcomes but triggered by specific signals when apoptosis is inhibited. Such overlaps highlight the evolving understanding of cell death modalities, where experimental assays can further differentiate them based on these features.[67][68]
AspectApoptosisNecrosis
InitiationProgrammed, regulated (e.g., via caspases)Accidental, unregulated (e.g., due to injury)
Energy RequirementATP-dependentATP-independent
MorphologyCell shrinkage, blebbing, apoptotic bodies; intact membraneCell swelling, rupture; membrane breakdown
BiochemistryDNA laddering, caspase activationRandom DNA degradation, calpain/PARP activation
InflammationNon-inflammatory; rapid phagocytic clearance prevents DAMP releasePro-inflammatory; DAMP release triggers immune response

Experimental Assays

Experimental assays for apoptosis detection encompass a range of techniques that identify key biochemical and morphological hallmarks, such as DNA fragmentation, phosphatidylserine (PS) exposure, and caspase activation, enabling quantification in both in vitro and in vivo settings. The terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay is a widely used method to detect DNA strand breaks resulting from endonuclease activity during apoptosis. In this assay, terminal deoxynucleotidyl transferase incorporates labeled dUTP into the 3'-OH ends of fragmented DNA, allowing visualization via fluorescence microscopy or flow cytometry, particularly in fixed tissues or cells.[70][71] Flow cytometry combined with annexin V and propidium iodide (PI) staining provides a sensitive approach to assess early apoptosis by detecting the externalization of PS on the plasma membrane, a hallmark of apoptotic progression. Annexin V, a calcium-dependent phospholipid-binding protein, binds specifically to exposed PS, while PI enters cells with compromised membranes to distinguish viable, early apoptotic (annexin V-positive/PI-negative), late apoptotic (annexin V-positive/PI-positive), and necrotic cells. This dual-staining method allows for high-throughput quantification of apoptotic populations in heterogeneous samples.[72][73] Western blotting for caspase cleavage products serves as a confirmatory technique to detect the proteolytic activation of executioner caspases, such as caspase-3, which are cleaved into active fragments during apoptosis. Antibodies specific to cleaved caspase-3 or its substrates, like poly(ADP-ribose) polymerase (PARP), reveal bands corresponding to these fragments, providing evidence of the caspase cascade in cell lysates. This method is particularly useful for validating pathway involvement in response to apoptotic stimuli.[74][75] Advanced assays include fluorometric measurements of caspase activity, which utilize synthetic substrates like DEVD-AMC that release fluorescent AMC upon cleavage by active caspases, enabling real-time kinetic analysis in cell extracts or live cells. Time-lapse imaging captures dynamic morphological changes, such as membrane blebbing, where high-resolution microscopy tracks the formation and resolution of blebs driven by actomyosin contraction in apoptotic cells. Microscopic visualization of nuclear morphology provides a direct means to confirm apoptosis through characteristic changes like chromatin condensation and fragmentation. In apoptotic cells, including leukocytes such as neutrophils or monocytes, Hoechst 33342 staining visualizes condensed chromatin and fragmented nuclei (karyorrhexis) as brightly fluorescent structures under fluorescence microscopy. Giemsa (or May-Grünwald-Giemsa) staining reveals these features under light microscopy as pyknotic, condensed, and fragmented nuclei.[76][12] Additionally, CRISPR/Cas9-mediated knockouts of genes in apoptotic pathways, such as BCL2 or CASP3, validate functional roles by assessing altered cell death responses post-knockout.[77][78][79] Due to overlaps with other forms of cell death, such as necrosis or pyroptosis, multi-parameter approaches combining multiple assays—e.g., annexin V/PI with TUNEL or caspase activity—are essential for accurate discrimination and comprehensive profiling of apoptosis. In vivo studies often employ ethical model organisms like zebrafish to minimize animal suffering while adhering to the 3Rs principles (replacement, reduction, refinement); for instance, transparent zebrafish larvae allow non-invasive imaging of apoptotic events without terminal procedures. Recent advancements, including single-cell RNA sequencing (scRNA-seq) in 2024, have enabled the dissection of apoptotic transcriptomes, revealing dynamic gene expression profiles in individual cells undergoing apoptosis, such as upregulation of BCL2 family members.[80][81][82]

Biological Roles

In Development and Tissue Homeostasis

Apoptosis plays a pivotal role in embryonic development by sculpting complex structures through the precise elimination of superfluous cells. In the nematode Caenorhabditis elegans, development of the hermaphrodite involves the generation of 1090 somatic cells, of which 131 undergo programmed cell death in a highly stereotyped manner, ensuring proper organ formation and lineage specification.90158-1) In vertebrates, apoptosis is essential for limb morphogenesis, particularly through interdigital cell death that separates developing digits; this process involves mesenchymal cells in the interdigital zones undergoing apoptosis under the regulation of bone morphogenetic proteins (BMPs), which trigger caspase activation and DNA fragmentation. Hox genes further modulate this apoptotic program in limb development, with Hoxd cluster members like Hoxd13 influencing the spatial and temporal patterns of cell death to establish digit identity and separation. Dysregulation of apoptosis during development disrupts tissue architecture and leads to congenital malformations. For instance, impaired interdigital apoptosis results in syndactyly, where digits remain fused due to persistent webbing, as observed in genetic models with mutations in BMP signaling or Hox pathways that fail to initiate sufficient cell death. This balance between proliferation and apoptotic elimination is crucial; excessive survival of cells can lead to overgrowth or fusion defects, while insufficient apoptosis may cause incomplete sculpting, highlighting apoptosis as a key regulator of developmental patterning. In adult tissue homeostasis, apoptosis maintains cellular equilibrium by counterbalancing proliferation and replacing senescent or damaged cells. In epithelial tissues, such as the intestinal lining, apoptotic extrusion of cells from the monolayer ensures continuous renewal without disrupting barrier function, with caspases facilitating the coordinated shedding of apoptotic cells at a rate of approximately one cell every 20 seconds per villus (in mouse models) to sustain tissue integrity.[83] Among lymphocytes, the vast majority of activated T cells—often over 90% of the expanded effector population—undergo apoptosis following immune challenges to prevent chronic inflammation and restore steady-state numbers, a process mediated by Fas-FasL interactions.00704-3) Similarly, in mammalian oogenesis, apoptosis eliminates more than 99% of germ cells during fetal development, selectively removing excess oocytes through follicular atresia to optimize reproductive potential and ensure oocyte quality.

In Immune Response and Defense

Apoptosis plays a pivotal role in shaping the adaptive immune response by eliminating autoreactive lymphocytes during their development, thereby establishing central tolerance. In the thymus, thymocytes expressing T cell receptors (TCRs) with high affinity for self-antigens undergo negative selection through apoptosis, preventing the maturation and export of potentially autoreactive T cells to the periphery.[84] Similarly, in the bone marrow, immature B cells bearing self-reactive B cell receptors (BCRs) are subjected to negative selection via antigen-induced apoptosis, which curbs the production of autoantibodies and maintains self-tolerance.[85] These processes ensure that only non-self-reactive lymphocytes proceed to populate secondary lymphoid organs. Beyond development, apoptosis regulates peripheral immune homeostasis through activation-induced cell death (AICD), a mechanism that curbs excessive lymphocyte expansion following antigen stimulation and prevents lymphoproliferation. AICD primarily targets activated T cells, inducing their programmed death via interactions between Fas ligand (FasL) and Fas receptor, thus limiting potential autoimmune responses or chronic inflammation.[86] In immune defense, cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells actively induce apoptosis in target cells, such as those infected by viruses or transformed by cancer, employing granule exocytosis of perforin and granzymes or death receptor ligation via FasL to dismantle infected cells without widespread tissue damage.[87] These extrinsic pathway-mediated killings, which involve caspase activation, are essential for pathogen clearance and tumor surveillance.[88] Pathogens can subvert apoptotic pathways to evade host defenses, as exemplified by HIV-1, which exploits apoptosis to deplete CD4+ T cells, contributing to immunodeficiency through pathways involving integrated stress responses and direct viral induction of cell death.[89] More recently, research from the 2020s has highlighted SARS-CoV-2's role in inducing apoptosis in lung epithelial and alveolar cells, exacerbating tissue damage and contributing to acute respiratory distress syndrome in severe COVID-19 cases.[90] Overall, apoptosis in the immune system maintains immunological tolerance by selectively removing aberrant cells and controls inflammation by resolving effector responses, ensuring balanced immunity without autoimmunity or unchecked proliferation.[85]

Implications in Disease

Defective Apoptotic Pathways

Defective apoptotic pathways, characterized by insufficient programmed cell death, contribute to the persistence and proliferation of abnormal cells, underpinning several diseases. In cancer, evasion of apoptosis is recognized as a core hallmark, enabling the survival of cells with oncogenic mutations that would otherwise be eliminated. This dysregulation often arises from alterations in key apoptotic regulators, allowing tumors to resist both intrinsic cellular safeguards and extrinsic death signals. In many cancers, overexpression of anti-apoptotic proteins such as Bcl-2 facilitates the survival of mutated cells by inhibiting mitochondrial outer membrane permeabilization and cytochrome c release in the intrinsic pathway. The t(14;18) chromosomal translocation, common in follicular lymphoma, drives Bcl-2 overexpression, promoting lymphoid cell accumulation and tumor progression. Similarly, inhibitors of apoptosis proteins (IAPs), including XIAP, are frequently upregulated in various tumors, where they bind and suppress caspases, thereby blocking the execution phase of apoptosis and enhancing cell survival under stress. Mutations in the tumor suppressor p53, which occurs in more than 50% of human cancers, disable the intrinsic apoptotic pathway by preventing p53-mediated transcription of pro-apoptotic genes like BAX and PUMA, allowing damaged cells to evade death and accumulate genetic instability.[91][92][93] Defects in apoptotic pathways also manifest in autoimmune disorders, where impaired cell death leads to the survival of autoreactive lymphocytes. In autoimmune lymphoproliferative syndrome (ALPS), germline or somatic mutations in the FAS gene encoding the Fas receptor disrupt the extrinsic apoptotic pathway, resulting in defective Fas-mediated apoptosis of activated T and B cells, lymphoproliferation, and autoimmunity. Systemic lupus erythematosus (SLE) involves defective clearance of apoptotic cells, leading to the accumulation of autoantigens and secondary necrosis, which triggers chronic inflammation and autoantibody production against nuclear components. A notable example of apoptosis evasion is observed in HeLa cells, derived from cervical cancer, where human papillomavirus (HPV) oncoproteins E6 and E7 inhibit p53 and Rb pathways, respectively, preventing apoptosis and sustaining immortalization; recent studies in 2025 have linked this mechanism in HPV-positive tumors to resistance against immunotherapy by promoting immune evasion alongside apoptotic suppression.[94][63][95][96]

Hyperactive Apoptotic Pathways

Hyperactive apoptotic pathways result in excessive programmed cell death, leading to progressive tissue atrophy and organ dysfunction across various pathologies. This overactivation disrupts normal cellular homeostasis, where unchecked caspase signaling and mitochondrial outer membrane permeabilization amplify neuronal or immune cell loss, ultimately contributing to disease progression. In neurodegenerative disorders, hyperactive apoptosis plays a central role in neuronal depletion. In Alzheimer's disease, amyloid-beta (Aβ) peptides induce apoptosis in neuronal cells through activation of the caspase cascade, including caspase-3 and -9, which cleave key substrates and promote cell demise. Similarly, in Parkinson's disease, the neurotoxin MPTP triggers dopaminergic neuron apoptosis by inhibiting mitochondrial complex I, generating reactive oxygen species, and activating intrinsic pathways involving Bax translocation and cytochrome c release. A prominent example of hyperactive apoptosis in infectious disease is observed in acquired immunodeficiency syndrome (AIDS), where human immunodeficiency virus (HIV) proteins such as Tat and Vpr hyperactivate the intrinsic apoptotic pathway in CD4+ T cells. Tat promotes apoptosis by inducing FOXO3a-mediated transcription of pro-death genes, while Vpr directly engages mitochondrial components like the adenine nucleotide translocator to initiate Bax/Bak oligomerization and caspase activation, leading to rapid depletion of these immune cells. This process contributes to the massive loss of approximately 101110^{11} CD4+ T cells over the disease course, driven by a daily turnover rate of about 3×1093 \times 10^9 cells in infected individuals. Beyond neurodegeneration and infection, hyperactive apoptosis exacerbates ischemia-reperfusion injury, where restoration of blood flow paradoxically triggers caspase-dependent death in affected tissues through oxidative stress and calcium overload. Recent 2023 investigations have also implicated hyperapoptosis in long COVID-associated cardiac complications, with SARS-CoV-2-induced mitochondrial dysfunction and inflammation promoting cardiomyocyte death and persistent myocardial impairment.

Therapeutic Targeting

Inhibitors of Apoptosis

Inhibitors of apoptosis represent a class of therapeutic agents designed to suppress excessive programmed cell death, particularly in degenerative conditions where hyperactive apoptotic pathways contribute to tissue loss, such as ischemia, non-alcoholic steatohepatitis (NASH), and heart failure. These strategies target key executioners of apoptosis, including caspases and regulators of the Bcl-2 family, to preserve viable cells and mitigate disease progression. By intervening in the intrinsic mitochondrial pathway or the extrinsic death receptor pathway, such inhibitors aim to restore cellular homeostasis without broadly disrupting normal physiology.[97] Pan-caspase inhibitors, which broadly block the activity of cysteine-aspartic proteases central to apoptosis execution, have been extensively explored in preclinical models of neurodegeneration and ischemia. For instance, Z-VAD-fmk, a cell-permeable irreversible pan-caspase inhibitor, has demonstrated neuroprotection in rodent models of focal cerebral ischemia by reducing infarct volume, caspase activation, and neuronal injury when administered post-ischemia. This compound attenuates downstream effects like cytochrome c release and DNA fragmentation, highlighting its potential for acute interventions in stroke where rapid cell death exacerbates brain damage. However, its translation to clinical use remains experimental due to challenges in delivery and specificity.[98][99][100] Another pan-caspase inhibitor, emricasan (IDN-6556), was advanced to clinical trials for NASH, a degenerative liver condition involving apoptotic hepatocyte loss and fibrosis. In Phase II studies during the late 2010s, emricasan reduced serum markers of apoptosis and inflammation, such as caspase-cleaved cytokeratin-18, but failed to improve key histological endpoints like fibrosis stage or ballooning in patients with F1-F3 fibrosis after 72 weeks of treatment. The trial's termination in 2019 was attributed to lack of efficacy and potential worsening of some liver features, alongside side effects like gastrointestinal issues, underscoring the difficulties in achieving sustained benefits in chronic settings.[101][102][103] Modulation of the Bcl-2 family offers another avenue to inhibit apoptosis by enhancing anti-apoptotic members like Bcl-2 and Bcl-xL, which prevent mitochondrial outer membrane permeabilization. Overexpression or pharmacological activation of Bcl-2 has shown neuroprotective effects in models of acute neural injury, such as ischemia-reperfusion, by stabilizing mitochondrial integrity and reducing Bax translocation. These approaches target hyperactive pro-apoptotic signaling in degenerative contexts, like neuronal loss in stroke, but face hurdles including delivery across the blood-brain barrier and long-term risks.[104][105] A major challenge with apoptosis inhibitors is their potential off-target effects, particularly the promotion of carcinogenesis through prolonged survival of mutated cells. Chronic suppression of apoptotic checkpoints in degenerative diseases may inadvertently foster tumor development, as observed in preclinical studies where sustained caspase inhibition accelerated neoplastic transformation. Thus, these therapies are best suited for acute applications, such as neuroprotection during ischemia, rather than indefinite use. Negative regulators like IAPs, which naturally inhibit caspases, can be indirectly bolstered to amplify anti-apoptotic effects, as their downregulation in heart failure exacerbates myocyte loss.[97][106]

Inducers of Apoptosis

Inducers of apoptosis encompass a range of pharmacological agents and therapeutic strategies designed to activate programmed cell death pathways, primarily targeting proliferative diseases such as cancer and certain infections. These approaches exploit vulnerabilities in cancer cells, including dysregulated apoptotic machinery, to selectively trigger death while minimizing harm to healthy tissues. Key mechanisms involve activation of intrinsic or extrinsic pathways, often through DNA damage, death receptor ligation, or inhibition of anti-apoptotic proteins. Chemotherapeutic agents like doxorubicin represent a cornerstone of apoptosis induction in cancer therapy. Doxorubicin intercalates into DNA, causing double-strand breaks that activate the tumor suppressor p53, which in turn upregulates pro-apoptotic genes such as BAX and PUMA to initiate mitochondrial outer membrane permeabilization and caspase activation. This p53-dependent pathway is essential for doxorubicin's cytotoxic effects, as evidenced in studies showing that p53-deficient cells exhibit reduced apoptosis and increased resistance.[107][108] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists offer a targeted alternative by engaging death receptors DR4 and DR5 on tumor cells, selectively inducing extrinsic apoptosis via caspase-8 activation and downstream effector caspases, with minimal toxicity to normal cells due to their resistance to TRAIL-mediated death. Clinical development has focused on recombinant TRAIL proteins and agonistic antibodies, which have shown efficacy in preclinical models of various solid tumors and hematologic malignancies.[28][109] BH3 mimetics, such as navitoclax, directly antagonize anti-apoptotic BCL-2 family proteins by mimicking BH3-only activators like BIM, thereby freeing pro-apoptotic effectors BAX and BAK to permeabilize mitochondria and amplify the intrinsic apoptotic cascade. Navitoclax binds with high affinity to BCL-2, BCL-XL, and BCL-W, restoring apoptosis sensitivity in malignancies reliant on these survival factors.[110][111] These inducers are particularly valuable in overcoming resistance conferred by BCL-2 overexpression, a common feature in cancers like chronic lymphocytic leukemia and non-Hodgkin lymphoma, where elevated BCL-2 sequesters BH3-only proteins and blocks mitochondrial apoptosis; BH3 mimetics like navitoclax circumvent this by competitively displacing activators, leading to rapid cytochrome c release and cell death. In preclinical models, such agents have restored sensitivity to standard chemotherapies in BCL-2-dependent tumors.[112][113] Chimeric antigen receptor (CAR) T-cell therapies enhance FasL-mediated apoptosis by engineering T cells to express Fas ligand (FasL), which binds Fas receptors on antigen-negative or resistant tumor cells, activating the extrinsic pathway through FADD and caspase-8 to promote bystander killing and mitigate antigen escape in heterogeneous tumors like lymphomas and solid cancers. This mechanism amplifies overall antitumor efficacy by extending apoptosis induction beyond CAR-targeted cells.[114][115] Therapeutic strategies often exploit defective apoptotic pathways in cancer cells, such as impaired p53 or upregulated inhibitors, by combining inducers with immunotherapies; for instance, PD-1 inhibitors like pembrolizumab sensitize tumors to apoptosis by reinvigorating cytotoxic T cells, which release granzyme B and FasL to trigger death receptor and mitochondrial pathways, enhancing responses in checkpoint-resistant malignancies.[116][117] Venetoclax, a selective BCL-2 inhibitor and BH3 mimetic, has gained prominence in acute myeloid leukemia (AML), where combinations with hypomethylating agents like azacitidine have demonstrated durable remissions; as of 2025, with ongoing expansions including an FDA submission under review for combination with decitabine/cedazuridine in newly diagnosed AML (PDUFA February 2026), achieving composite complete response rates of 66-67% in pivotal clinical trials such as VIALE-A.[118][119][120] Inhibitors of IAPs, such as xevinapant, are in Phase III trials as of 2025 for enhancing apoptosis in cancers like head and neck squamous cell carcinoma when combined with standard therapies.[121] Viral vectors facilitate gene therapy-based apoptosis induction by delivering pro-apoptotic transgenes, such as TRAIL or FHIT, directly to tumor sites; adenoviral or adeno-associated viral vectors encoding TRAIL have induced selective apoptosis in pancreatic and colon cancers in preclinical models, with tumor regression observed upon intratumoral administration due to amplified caspase activation.[122]

Apoptosis in Non-Animal Organisms

In Plants

Programmed cell death (PCD) in plants, often termed apoptosis-like PCD, is a genetically regulated process that eliminates superfluous or damaged cells, playing essential roles in development and stress responses, though it differs mechanistically from animal apoptosis due to the presence of rigid cell walls and vacuoles.[123] In plants, PCD facilitates tissue remodeling and defense without a circulatory system, enabling localized containment of cellular events to prevent widespread damage.[124] A prominent example of PCD in plant defense is the hypersensitive response (HR), a rapid, localized cell death triggered at pathogen penetration sites to restrict biotrophic invaders by depriving them of nutrients and activating systemic resistance signals.[124] During HR, reactive oxygen species (ROS) accumulation initiates signaling cascades that culminate in PCD, mirroring stress-induced death in other contexts.[125] In development, PCD drives aerenchyma formation in roots and stems under hypoxic conditions, where cortical cells undergo lysigenous death to create air channels for oxygen transport, enhancing adaptation to waterlogged soils.[126] Similarly, xylem differentiation involves PCD in vessel elements and tracheids, where cells deposit secondary walls before autolysis, forming hollow conduits for water conduction.[127] Mechanistically, plants lack true caspases but employ analogs like metacaspases, which are cysteine proteases activated by ROS to execute proteolysis during PCD, as seen in Arabidopsis where metacaspase-8 modulates ROS-induced death.[125] Vacuolar processing enzymes (VPEs), another class of cysteine proteases, contribute to vacuole-mediated cell death by processing substrates in acidic environments, playing key roles in HR and developmental PCD such as seed coat formation.[128] Recent research as of 2024 has highlighted the pivotal role of intracellular acidification alongside calcium signaling in regulating plant PCD.[129] Additionally, as of 2025, ACINUS has been identified as a putative integrant in plant PCD pathways.[130] Morphological hallmarks of plant PCD include DNA laddering and chromatin condensation, akin to animal apoptosis, though cell wall constraints limit membrane blebbing; instead, vacuolar collapse often drives rapid lysis.[131] Recent 2020s research highlights mitogen-activated protein kinase (MAPK) cascades in plants that propagate signals leading to PCD, analogous to components of the animal extrinsic pathway in coordinating immune responses.[132]

Evolutionary Conservation

Apoptosis, or programmed cell death (PCD), exhibits remarkable evolutionary conservation, with core components present from unicellular organisms to multicellular non-animals and animals. While the machinery is well-characterized in model animals like Caenorhabditis elegans (with CED-3 and CED-9 homologs) and conserved in mammals via caspases and Bcl-2 family proteins, variations reflect adaptations across taxa.[133][134][135] Pioneering work by John Sulston in the 1980s mapped 131 programmed cell deaths in C. elegans development.[136] In non-metazoans, fungi employ metacaspases—distant caspase relatives—for PCD-like responses to stress, cleaving arginine/lysine residues.[137][138] Protozoan parasites like Leishmania donovani and Blastocystis hominis show apoptosis-like features including DNA fragmentation and caspase-like activity.[139][140] Prokaryotes lack canonical apoptosis but utilize toxin-antitoxin systems for PCD under stress, such as in biofilms.[141] A 2025 study reported apoptotic bodies in phytoplankton, suggesting conservation of apoptosis in unicellular eukaryotes and pushing origins back to early eukaryotic evolution.[142] The evolution of apoptosis links to multicellularity, enabling tissue sculpting. Phylogenetic analyses show Bcl-2 family origins predate metazoans, with homologs in choanoflagellates and basal lineages, co-opted from ancestral stress responses.[143][144] This conservation highlights apoptosis as an ancient mechanism repurposed for complex life.

References

User Avatar
No comments yet.